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Abstract
Chronic wounds present a significant burden to patients, causing pain, impairing limb
function, and often resulting in the need for amputation. Treatment of chronic dermal wounds
is challenging, with current therapies showing limited efficacy in clinical trials. As galectin3 has been implicated in several wound healing processes, its efficacy as a therapeutic in skin
healing was investigated in this study. An electrospun gelatin scaffold loaded with galectin-3
was developed as a delivery system. The influence of human recombinant galectin-3 in skin
healing, when delivered topically and using an electrospun scaffold, was then investigated in
wild type and diabetic mice. Electrospun gelatin/galectin-3 scaffolds were developed having
an overall porosity of approximately 83% and average pore diameter of approximately 1.15
μm. The scaffolds supported the adhesion, deposition of matrix, and proliferation of human
dermal fibroblasts in vitro providing evidence that they are biocompatible. In vivo treatment
of wounds with topical galectin-3 and gelatin/galectin-3 scaffolds did not affect wound
closure, re-epithelialization or macrophage phenotypes in the wound, casting doubt on its
efficacy for these processes. Future work is required to elucidate the exact pathological
contexts in which galectin-3 might modulate inflammation in skin healing.
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Introduction

1.1 Skin, Cutaneous Wound Healing and Chronic Wounds
1.1.1

Skin Anatomy and Physiology

Skin is the largest organ in the human body, playing several important physiological roles
including water regulation, thermoregulation as well as acting as a barrier against
physical, chemical and biologic stresses (1, 2). Human skin is subdivided into three
layers: the epidermis, dermis and the hypodermis. The epidermis is the outermost layer
and is responsible for the skin’s barrier function. It is a cell dense layer consisting of
keratinocytes that synthesize the major structural protein found in the epidermis, keratin.
Also present in the epidermis are melanocytes, which produce melanosomes containing
melanin, giving skin its pigmentation and providing protection for cell nuclei from
ultraviolet light. Langerhans cells are also found in this layer and act as antigenpresenting cells (3). The dermis is the largest layer of the skin and is responsible for
protecting the body from mechanical injury (1, 4). The main structural component of
dermis is the extracellular matrix (ECM), which consists of proteins including reticulin,
elastin, and collagen (types I, III and V) (5). Collagen accounts for the majority of the
ECM and is responsible for the elastic and tensile properties of skin (4). The primary cell
type of the dermis is the fibroblast which acts to secrete ECM proteins (4). Upon reaction
to different stimuli, various leukocyte populations including macrophages can enter the
dermis through vascular networks (1). The subcutaneous tissue consists of lipocytes
separated by fibrous septa containing blood vessels and collagen, and plays a role in
buoyancy and providing energy storage (5).

1.1.2

Cutaneous Wound Healing

Normal cutaneous wound repair involves four overlapping phases of hemostasis,
inflammation, proliferation, and remodeling. Upon injury, the inflammatory phase is
initiated, with platelets aggregating in the wall of injured blood vessel to form a plug and
subsequently a fibrin network. This creates a clot to establish homeostasis (6).
Neutrophils are then recruited to debride the wound of foreign particles and bacteria.
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Neutrophil populations are removed from the eschar or become engulfed by
macrophages. In response to certain chemoattractants, including transforming growth
factor beta (TGF-β), monocytes infiltrate the wound and differentiate into macrophages
(7). Macrophages are central to development of granulation tissue and are responsible for
producing nitric oxide, pro-inflammatory cytokines such as tissue necrosis factor alpha
(TNF-α), interleukin 1 beta (IL-1β), IL-6, and IL-12, and growth factors including
fibroblast growth factor (FGF), epidermal growth factor (EGF), TGF-β, and platelet
derived growth factor (PDGF) (8, 9).
Within hours of initial injury, epithelial cell proliferation and migration is initiated
through the release of EGF, transforming growth factor alpha (TGF-α) and FGF, which
begins the re-epithelialization phase (9). The epidermis and the basement membrane
separate via dissolution of their hemidesmosomal links and subsequent keratinocyte
migration over the dermis separates the eschar from viable tissue (6, 7). Behind the
leading edge of migration, the keratinocytes proliferate and mature, eventually restoring
the barrier function of the epithelium (6). Macrophages secrete TGF-β that signals
fibroblasts to migrate into the granulation tissue and produce new ECM components.
These components, including fibronectin, hyaluoronic acid, and collagen, serve as a
scaffold for cell infiltration of the granulation tissue through cell migration (7). The
secretion of vascular endothelial growth factor (VEGF) and PDGF by activated platelets
and macrophages initiates angiogenesis (6, 9). This process results in the formation of
blood vessels that support the newly formed granulation tissue by providing a nutrient
and oxygen supply to sustain cell growth and metabolism (7). TGF-β also stimulates the
differentiation of fibroblasts into myofibroblasts, highly contractile cells which contract
the wound, pulling the edges together to achieve closure (6, 9).
During the remodeling phase endothelial cells, macrophages, and myofibroblasts undergo
apoptosis or exit the wound. The wound consists predominantly of a type III collagen,
ECM proteins and is largely acellular. It is subsequently remodeled into a type I collagen
matrix by matrix metalloproteinases (MMPs) secreted by fibroblasts, macrophages, and
endothelial cells, although the remodeled tissue never fully regains the tensile strength of
the original skin (6, 7).
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1.1.3

Chronic Dermal Wounds

A dermal wound is classified as chronic if it has failed to progress through the normal
sequences of the wound healing process within a twelve week period (10), resulting in
the impairment of normal tissue function and anatomy (11). Chronic wounds are
characterized by residual inflammation, cellular senescence, lack of cell signaling, and
bacterial colonization (11). A variety of factors can contribute to their development,
including vascular insufficiency, diabetes, malnutrition, patient age, pressure, infection,
and edema (12). These wounds become a significant burden to the patient, as they can be
painful, impair limb function, and result in sepsis or the need for amputation (12).
Furthermore, they pose a significant burden to the Canadian healthcare system, with the
average cost of treatment of a chronic wound being $10,376 (13). The most common
types of chronic wounds, which include venous, arterial, and diabetic foot ulcers (DFUs),
are discussed below (11, 14).
Venous ulcers affect around 0.1% of the Canadian population. They are more common in
older patients although early onset can begin in patients in their twenties (15). The skin in
these patients becomes injured as a result of limb edema and venous hypertension, which
can occur due to venous thrombosis, venous valve reflux, or from damage to the venous
wall or valves (16, 17). The ulcers develop in the gaiter region of the lower leg, form with
an irregular border, and usually contain granulation and fibrinous tissue. Patients
typically experience aching of the legs after long periods of standing in addition to leg
heaviness and swelling (11).
Up to 10% of patients with lower limb ulcers have arterial insufficiency (18). Arterial
ulcers can result from any process that obstructs arterial flow, which includes vasculitis,
microthrombotic disease, sickle cell disease, and atherosclerosis. Progressive
atherosclerosis is the most common cause for arterial ulcers, where smoking, poorly
controlled hypertension and diabetes mellitus can cause high levels of circulating
cholesterol and triglycerides, leading to lipid deposition in arterial vessel walls which
causes arteries to become stenotic (19). Atherosclerosis causes poor perfusion, impairs
skin oxygenation, and causes breakdown of the tissue. The wounds typically develop at
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bony prominences or distal points and have dry necrotic wound beds, demarcated
borders, and lack granulation tissue (11).
Pressure ulcers affect up to 26% of patients in Canada (20) and are common in patients
with impaired mobility or sensory perception, malnutrition, and fecal incontinence (11,
12). They can start to develop in patients after just 2 hours of compression of soft tissues,
and commonly occur when there is contact between a surface and bony prominence (19).
Several factors can lead to the development of a pressure ulcer including sustained shear
forces or forces perpendicular to the point of contact, friction that can lead to blisters or
erosions, loss of elastin in aged skin that decreases resistance to pressure, and prolonged
exposure to moisture (sweat, urine, fecal) that can result in breakdown of the skin (19).
These factors result in localized tissue necrosis that leads to tissue injury (11).
Currently in Canada, 3.5 million individuals live with diabetes (21) and up to 25% of
these patients will be affected by a DFU in their lifetime (22). Neuropathy, vascular
disease, and previous foot ulceration are major risk factors for the development of a
diabetic ulcer (19, 23). Neuropathy can impair a patient’s joint mobility and cause an
imbalance of pressure distribution on the foot, which can lead to the formation of calluses
(19, 23). Additionally, the loss of sensation in the foot can result in repetitive injury that
these patients are unable to detect (19, 23). Ischemia resulting from vascular disease
impairs oxygenation of the feet leads to dry skin and results in breakdown of the tissue
(11). DFUs are commonly located on the plantar surfaces of the feet where they are
exposed to repetitive injury, with foot deformities and reduced joint mobility causing
callus formation at abnormal pressure points (11). DFUs are a highly problematic
outcome of diabetes, as they are the most common cause of non-traumatic lower limb
amputations, with 15-20% of DFU patients requiring amputation (10). Furthermore, these
amputations are associated with a high incidence of mortality (24). In Canada, the
Canadian Diabetes Association reported that 30% of patients with diabetes will die within
one year of amputation and 69% of patients with amputations will not survive past 5
years (13). In addition to their comorbidities, DFUs burden the Canadian healthcare
system, costing $150 million annually (13).
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1.1.4

Current Treatments for Chronic Wounds

Current management of chronic wounds is based on TIME guidelines which were first
described by Schultz et al. (25). The TIME acronym refers to Tissue, Infection, Moisture
Balance, and Wound Edge Management (26). In treating chronic wounds, the first step is
to remove any necrotic tissue, which can impair healing. This non-viable tissue is
removed through debridement that can be conducted using surgery, enzymatic digestion,
or using biologic or mechanical methods (27). Bacterial infection of a wound can both
delay healing and lead to systemic infections. To address this problem, wounds can be
cleaned with water or saline and dilute acetic acid when they are prone to infection.
Topical antimicrobial agents, including silver, gel beads for slow-release of cadexomer
iodine, and manuka honey are also recommended for treatment of superficial wound
infection (27). Moisture retentive dressings can be used to maintain sufficient moisture
within the wound while controlling exudate. There are several types of dressings
available although their applicability depends on the nature of the wound including level
of exudate, depth and area of the injury, healing stage, and skin type (26, 27). Many
biologic dressings are also available and are applied with the intent of creating a
microenvironment supportive of healing. However, the efficacy of dressings is often
specific to the type of chronic wound or underlying disease and there is often limited
clinical support for their use (27).
In addition to wound management, many adjunctive therapies exist for the treatment of
chronic wounds including use of topical agents, bioengineered dressings, hyperbaric
oxygen therapy, and negative pressure wound therapy. Currently, most topical agents
available for chronic wound treatment target infection or have anesthetic properties (27).
RegranexTM is a topical formulation of PDGF and is currently the only growth factor
approved by the Food and Drug Administration for the treatment of DFUs (10). Although
clinical trials have shown an increase in wound closure with use of RegranexTM relative
to placebo controls (27), other studies in animal models have shown it to be less effective
for full thickness wounds relative to other drug targets (28). Use of three or more tubes of
gel is also associated with an increased risk of cancer-related mortality (10).
PROMOGRAN® Matrix is another topical dressing agent used to inhibit protease
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activity and is approved for use in chronic wounds (27). It has been shown to improve
microcirculation in venous ulcers (29); however, a randomized controlled trial failed to
demonstrate that PROMOGRAN® Matrix can significantly accelerate healing relative to
controls (30).
There are a growing number of bioengineered substitutes being developed for use in
chronic wounds (27, 31, 32). The Integra Bilayer Wound Matrix is an acellular matrix
consisting of a dermal layer of type I bovine collagen and shark chondroitin-6-sulfate and
an epidermal layer of silicone (31). Case reports have described Integra Bilayer Wound
Matrix as promoting healing in DFUs when used in combination with other treatment
methods (33). A retrospective study reported an 81% healing rate of lower extremity
wounds although only 16 patients were included in the study and not all wounds were
considered chronic (34). Another acellular dressing is the OASIS® Wound Matrix which
is made from porcine intestinal submucosa (27). A multicenter trial of patients with
venous ulcers reported that a higher number of patients achieved complete wound closure
when OASIS® was used relative to compression bandaging alone, although adverse
events, including skin injury and infection, were also reported in two patients (31). Skin
substitutes containing cells include Dermagraft® and Apligraf®. Dermagraft® is a
polyglactin scaffold implicated for treatment of DFUs. It contains human, neonatalderived fibroblasts and several growth factors, including TGF-β1, TGF-β3, TGF-α,
heparin binding epidermal growth factor, PDGF-A, insulin-like growth factor,
keratinocyte growth factor (KGF), and VEGF (10). Apligraf® is a matrix intended for
use in diabetic and venous ulcers. It contains a stratum corneum of differentiated
keratinocytes a dermal layer consisting of type I bovine collagen fibrils (10, 27). There is
a stronger body of evidence supporting use of these products for treating chronic wounds,
as numerous studies report their efficacy, showing improvements in healing relative to
controls (27, 31). However, adverse events have been reported in some studies and multicenter center studies for treatment of foot ulcers are still lacking (31, 35).
For treatment of DFUs, hyperbaric oxygen therapy (HBOT) and negative pressure wound
therapy can also be conducted in conjunction with other treatments. HBOT entails the
delivery of 100% oxygen to the wound, usually for 90 minutes at 1.5-3.0 atmospheres. It
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is typically conducted in daily sessions and is intended to increase oxygen saturation of
the blood (36). Although there is some evidence to support its efficacy in healing DFUs
in patients with concomitant ischemia (36), Health Quality Ontario reported that there
was insufficient evidence for its use as adjunct to standard therapy for patients with nonhealing DFUs due to inconsistent results in randomized controlled trials (37). Negative
pressure wound therapy can also be used for DFU treatment and entails the delivery of
sub atmospheric pressures to the wound bed using a vacuum pump in order to promote
cell proliferation in the wound bed (38). Although it is effective for post-surgical
treatment of acute wounds, its efficacy has not yet been shown for chronic, non-healing
wounds (38, 39).

1.2 Pathophysiology of Chronic Wounds
As previously discussed, chronic wounds do not follow the regular wound healing
process, resulting in failure to achieve closure (40). Rather, these wounds have decreased
levels of growth factors essential for the normal wound healing response including TGFβ and VEGF, preventing essential processes such as re-epithelialization and angiogenesis.
Additionally, chronic wounds have increased levels of expression of inflammatory
cytokines, such as IL-1, IL-6, and TNF-α, which enhance the immune response and
increase local inflammation (41). As a result, there is a continuous, self-perpetuating
cycle of inflammation, preventing progression into the proliferative phase of healing and
leaving the wound in a non-healing state regardless of wound management and
intervention (12, 40). Several underlying factors lead to the continuous state of
inflammation, including impaired processes such as re-epithelialization and granulation
tissue formation, imbalances in proteolytic activity, bacterial colonization resulting in the
development of biofilms, the accumulation of advanced glycation end products (AGEs, in
diabetic patients), and the accumulation of oxidative stress in the wounds (12, 41). The
independent role each of these factors plays in the perpetuating inflammation is discussed
in depth below.
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1.2.1

Impaired Re-epithelialization and Granulation Tissue
Formation

In chronic wounds, keratinocytes lack the ability to migrate, properly differentiate, and
proliferate (41). Keratinocyte migration is impeded due to decreased levels of expression
of EGF, FGF and TGF-α and their proliferation is reduced due to lower levels of KGF (9,
42). Nuclear localization of β-catenin and overexpression of c-Myc also impede epithelial
cell migration and supress their terminal differentiation (43). Together, these factors
impede re-epithelialization as they prevent keratinocytes at the edge of the wound from
migrating to form an epithelial barrier (41, 44).
Chronic wounds also show a significant deficiency in granulation tissue formation. This
is thought to be due to the overproduction of anti-angiogenic cytokines along with
reduced production of pro-angiogenic cytokines and the sequestering of growth factors
(45). Fibroblasts exhibit a phenotypic change in addition to decreased migration and
proliferation (41). Their migration and secretion of collagenase is hindered, due to
decreased levels of FGF-2 (9). Neovascularization is impaired due to decreased levels of
VEGF and FGF-2 (9). Upon treatment with VEGF and FGF-2, diabetic mice have
displayed significantly improved angiogenesis and accelerated wound healing (42).
Levels of VEGF are decreased due to reduced amounts of TGF-β1 in the wounds, which
acts to upregulate VEGF expression (9). Chronic wounds are also characterized by lower
levels of PDGF, further impeding angiogenesis (42). Finally, lowered levels of TGF-β1
decrease levels of fibronectin, collagen, and protease inhibitors, hindering new ECM
formation (9).

1.2.2

Imbalance of Proteolytic Activity

A balance of activity between proteases and their inhibitors is required for the normal
wound healing process to occur, as they play a functional role in the maintaining the
integrity of the ECM and controlling its degradation to facilitate migration of cells into
the wound (42, 46). In chronic wounds, this delicately controlled balance in protease and
inhibitor levels is offset, with increased levels of MMPs and decreased levels of tissue
inhibitor of metalloproteinases (TIMPs) being well documented in chronic wounds in
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both animal models and studies investigating human chronic wound exudate (42, 47).
These changes have been attributed to a lack of TGF-β1 in chronic wounds, which lowers
TIMP levels by inhibiting their secretion by fibroblasts (42). Chronic wounds also exhibit
a sustained increase in pro-inflammatory cytokines including IL-1β and TNF-α, which
increase production of MMPs, including MMP-1, MMP-2, MMP-3, MMP-9, and MMP13 while reducing synthesis of TIMPs (9, 46). Moreover, the elevation of certain MMPs
can activate other MMPs, triggering further increases in MMP levels (42). Increased
MMP activity degrades ECM, inhibits cell migration, and reduces fibroblast proliferation
and collagen deposition (12). MMPs have also been shown to degrade growth factors and
their target cell receptors, including EGF/epidermal growth factor receptor (EGFR) and
PDGF/platelet derived growth factor receptor further impairing the wound healing
cascade (9, 46). This enhanced proteolytic activity, taken together with insufficient
angiogenesis in chronic wounds, contributes to the inability to form proper granulation
tissue (9).

1.2.3

Biofilm Formation

Bacterial colonization of chronic wounds is also known to play a contributing role in
delayed healing, although the direct causal relationship in etiology is yet to be established
(48). Upon formation of the wound, the resulting loss in barrier function leaves the
wound susceptible to infection (23). Bacteria commonly found in wounds include
Staphylococcus aureus, Pseudomonas aeruginosa and β-haemolytic streptococci and
counts over 105 bacteria per gram of wound tissue are considered detrimental to healing
(12). Bacteria secrete a polymeric matrix adherent to the wound, forming a biofilm that is
an environment optimal for their survival, as this matrix is resistant to both the innate
immune mechanisms and antimicrobial agents (48, 49). Biofilms contribute to
inflammation due to their effect on neutrophils and macrophages. Specifically, biofilms
inhibit neutrophil chemotaxis and degranulation as well as preventing them from
ingesting bacteria, resulting in increased secretion of pro-inflammatory cytokines. They
also prevent the phagocytosis of neutrophils by macrophages, causing further
dysregulation of inflammation (48). In animal models, biofilms have also been shown to
delay re-epithelialization (50).
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1.2.4

Advanced Glycation End Products

AGEs are compounds formed through the Maillard reaction, which is a reaction that
occurs between the amino groups of proteins and carbonyl groups of reducing sugars
(51). AGEs are continuously produced in the body, but accumulate with the presence of
hyperglycemia or oxidative stress (52). Higher levels of AGEs in skin have been
associated with increased patient age, diabetes, as well as the presence of an ulcer in
diabetic patients and there is a large body of evidence implicating their role in the
pathogenesis of impaired diabetic wound healing (52, 53). AGEs can crosslink type I
collagen which results in its decreased solubility and increased rigidity (52). They can
also form on both laminin and type IV collagen, impairing both matrix-matrix
interactions and cell-matrix interactions (54). Soluble plasma proteins, including albumin,
fibrinogen, immunoglobulin, and low-density lipoprotein can also become glycated,
altering their structure and function (51, 54). Glycated albumin plays a role in platelet
activation and aggregation and glycated immunoglobulin is associated with inflammation
(51).
AGEs can also affect the function of wound healing cell types. In vitro studies have
associated AGEs with impaired keratinocyte migration and proliferation (55). They have
also been implicated in promoting apoptosis, inhibiting proliferation, and reducing
secretion of ECM proteins by fibroblasts, including proteoglycans and hyaluronic acid
(52). AGEs can also interact with AGE receptors on macrophages and endothelial cells,
which causes oxidative stress and activates nuclear factor kappa-light-chain-enhancer of
activated B cells (nf–κB). NF- κB increases production of pro-inflammatory cytokines
including IL-1α, IL-6, and TNF-α (51). AGE binding to AGE receptors also increases
production of vascular cell adhesion protein 1 and intracellular adhesion molecule 1
(ICAM-1), which contribute to inflammation. The production of TNF-α results in
increased production of reactive oxygen species (51). Sustained inflammation and
oxidative stress further exacerbate AGE formation by increasing expression of AGE
receptors through a positive feedback loop (52).
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1.2.5

Oxidative Stress

Wound fluid in patients with non-healing chronic wounds has shown significantly higher
levels of oxidative stress relative to wound fluid in patients with healing wounds (17).
Oxidative stress occurs when there is excessive generation of reactive oxygen species
(ROS) relative to the antioxidant capacity (44). It can cause serious cellular damage by
impairing mitochondrial function (56). Elevated levels of ROS are also associated with
supporting migration of inflammatory cells into the wound, upregulating ICAM-1, which
damages endothelial cells and facilitates recruitment of leukocytes, and impairing
keratinocyte migration in vitro (47).
Skin has a number of antioxidants including glutathione, ascorbic acid, and vitamin E,
which are involved in infection control as well as reducing oxidative stress that is
generated from inflammation in acute wounds (47). Chronic wound patients have been
shown to have decreased levels of vitamins A and E. Lower limb ulcers have also been
found to have decreased levels of selenium, a cofactor to glutathione peroxidase, as well
as lower glutathione peroxidase activity (47). Lower levels of antioxidants combined with
decreased antioxidant enzyme activity can debilitate antioxidant defense against
oxidative stress (47). In patients with venous leg ulcers, iron overload also plays a
contributing role to oxidative stress. Patients with venous leg ulcers have been shown to
have higher levels of iron with concomitant elevation of MMP-9, suggesting that elevated
iron deposits are released through activation of MMPs. Iron overload causes oxidative
stress through the production of ROS including superoxide, nitric oxide, hydrogen
peroxide, and peroxynitrite (17).
Hyperglycemia resulting from diabetes can result in the over activation of several
pathways. One such pathway is the hexosamine pathway, which inhibits the activity of
glucose-6-phosphate dehydrogenase and limits the formation of nicotinamide adenine
dinucleotide phosphate-oxidase (NADPH). Increased proteinase kinase C activity can
also activate NADPH, depleting it (44). NADPH oxidase is required for the formation of
reduced glutathione and nitric oxide, which act to neutralize reactive oxygen species;
hence its depletion contributes to oxidative stress (44, 57). The polyol pathway,
responsible for converting glucose to fructose, can also become over activated, resulting
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in further depletion of NADPH oxidase. Over production of fructose through this
pathway also contributes to the formation of AGEs, which accumulate with
hyperglycemia as previously discussed (57). AGE binding to activated AGE receptors
leads to the production of cytosolic ROS and the activation of NADPH oxidase, further
sources of oxidative stress and cellular dysfunction (51, 58). Finally, the combination of
hyperglycemia and presence of free radicals can activate the PARP pathway, further
exacerbating oxidative stress (57).
In summary, several factors act in combination to perpetuate the inflammatory response
in chronic wounds, which plays an integral role in preventing a wound’s progression
through the normal wound healing cascade (40). The consequences of remaining in this
non-healing inflammatory state are severe, as wounds do not achieve closure, leaving the
patient with a high risk of amputation (10), and consequently, at a high risk for mortality
following amputation (24). Therefore, due to poor patient outcomes and limited treatment
options, it is imperative that new treatment options be pursued. In light of the current
knowledge on chronic wound pathology discussed above, new approaches for the
treatment of chronic wounds should focus on modulating the inflammatory response,
such that the proliferative phase of inflammation can be activated and therefore, the
normal wound healing response achieved.

1.3 Galectin-3 as a Therapeutic for Chronic Wounds
Matricellular proteins are non-structural components of the extracellular matrix that
become upregulated during wound healing and pathological processes. During the wound
healing process, they act spatially and temporally to control specific cell behaviours
(Figure 1.1) (59). Galectin-3 is a matricellular protein implicated in several inflammatory
and immunomodulatory processes (60), making it an ideal candidate for treatment of
chronic wounds. It has shown the ability to influence monocyte and macrophage
migration (61), increase clearance of neutrophils (62), and regulate alternative
macrophage polarization (63), all processes that can contribute to modulating the
inflammatory response. Therefore, it is hypothesized that the use of galectin-3 will be
effective in promoting healing in chronic wounds by stimulating the proliferative phase
of healing.
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Figure 1.1 – Upregulation of matricellular proteins during the wound healing
response: Matricellular proteins upregulated during the wound healing response include
galectin-3, osteopontin, thrombospondin 1 (TSP-1), tenascin-c (TN-C), thrombospondin
2 (TSP-2), periostin, cysteine-rich angiogenic inducer 61 (CCN1), and connective tissue
growth factor (CCN2). Galectin-3 expression peaks at day 1 following wounding in mice
and persists throughout the inflammatory process (64). Reprinted with permission from
Hamilton D, Walker J, Kim S, Michelsons S, Creber K, Elliott C, et al. Cell-matrix
interactions governing skin repair: matricellular proteins as diverse modulators of cell
function. Research and Reports in Biochemistry. 2015:73 (64). Copyright © 2015, Dove
Press Ltd.
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1.3.1

Protein Structure

Galectin-3 is a protein consisting of 250 amino acids, separated into two distinct domains
(Figure 1.2) (65). The carbohydrate recognition domain (CRD) of this protein accounts
for approximately 130 amino acids and is globular in structure (66). The CRD domain
contains S-lectin motifs that provide the protein with the ability to bind β-galactosides, a
property shared by all proteins in the Galectin family (67, 68), as well as a nuclear export
signal (69).
In addition to its CRD, Galectin-3 contains an amino terminal domain, which spans
approximately 120 amino acids and contains a highly conserved tandem repeat rich in
proline, glycine and tyrosine (66, 70). The N-terminus contains a 12 amino acid leader
sequence that is required for Galectin-3 secretion (66). Within this leader sequence
serine6 can be phosphorylated, a process which significantly reduces binding to its
ligands (laminin and mucin) and may act as an on/off switch for its ability to bind to
sugars (71). The N-terminal domain also enables the formation of oligomers and is
required for full biological function of the protein, including its role in modulating cell
adhesion and inducing intracellular signalling (70, 72). Galectin-3 has been detected
within cells, localized in the nucleus and cytoplasm, and has also been described outside
of the cell, despite its lack of a known transmembrane domain and sequence (66, 73). It
has been found to interact with a variety of wound healing cell types including,
keratinocytes, fibroblasts, monocytes and macrophages (61, 74, 75).
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Figure 1.2 – Domains and structures of recombinant human galectin-3: Human
recombinant galectin-3 is a protein consisting of 250 amino acids. It features a 120 amino
acid N-terminal region that contains a leader sequence and a tandem repeat region rich in
proline, glycine and arginine. It also comprises of a CRD containing a β-galactoside
binding region and a sequence required for nuclear export.
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1.3.2

Role in Inflammation

Galectin-3 has been demonstrated to influence a variety of processes associated with
inflammation through its interaction with various cell types including neutrophils,
monocytes, and macrophages. In the initial stages of inflammation, neutrophils are
recruited to the wound to eliminate foreign particles and bacteria. In vitro studies have
shown that recombinant human galectin-3 can activate neutrophils in a dose-dependent
manner, through a process involving its CRD (76). A study investigating NADPH
oxidase activity revealed that galectin-3 activated exudate neutrophils, with increased
activity corresponding to increased surface-bound protein, while activity was unaltered in
peripheral neutrophils (77). In addition to neutrophil activation, galectin-3 has shown to
facilitate neutrophil adhesion to laminin in vitro and has been implicated in the
recruitment of neutrophils in a murine model of cutaneous infection (78, 79).
The inflammatory phase of healing also involves the recruitment of monocytes to the
wound, which differentiate into macrophages of varying phenotypes that play distinct
roles in inflammatory processes (80). Galectin-3 induces monocyte migration in vitro,
stimulating chemotaxis at high concentrations and chemokinesis at lower concentrations.
A migratory effect from galectin-3 is also observed in macrophages (61). Migration in
both monocytes and macrophages is increased in the presence of fibronectin, suggesting
that galectin-3 may mediate linkage of these cells to fibronectin (81). One of
macrophage’s roles in inflammation is to rid the wound of neutrophils, ingesting them
and inducing their apoptosis (80). In vitro studies suggest that galectin-3 can influence
this process as addition of exogenous galectin-3 increases apoptotic neutrophil uptake in
macrophages. It has also been postulated that galectin-3 acts as an opsonin, linking the
phagocytic macrophages to the neutrophils (62). A study conducted by MacKinnon et al.
investigated the effect of galectin-3 on macrophage activation in bone marrow derived
macrophages in vitro and in resident lung and recruited peritoneal macrophages in vivo.
Interestingly in all macrophages derived from galectin-3 deficient mice, IL-4/IL-13induced M2 macrophage polarization was inhibited, suggesting that galectin-3 is
involved in the regulation of alternative macrophage activation (63). A summary of
macrophage activation and polarization is shown in Figure 1.3.
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Figure 1.3 – Macrophage activation and polarization: Monocytes can undergo
classical activation in the presence of interferon gamma (IFN-γ) and lipopolysaccharides
(LPS) or TNF-α into M1-polarized macrophages, which are associated with
inflammation. M1 macrophages produce inducible nitric oxide synthase (iNOS) as well
as pro-inflammatory cytokines. In mice, markers of M1 macrophages include iNOS,
chemokine ligand 9 (CXCL9), CXCL 10, and CXCL11. Monocytes can undergo
alternative activation through stimulation with IL-4 or IL-13 into M2-polarized
macrophages. M2 are associated with tissue remodeling and secrete arginase I and antiinflammatory cytokines. M2 markers in mice include arginase I, Mrc I, Fizz I, Ym1, and
Ym 2 (8, 80, 82).
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1.3.3

Role in Angiogenesis

Galectin-3 has been shown to induce angiogenesis both in vitro and in vivo. In vitro, the
protein stimulated capillary tube formation of human umbilical cord endothelial cells
grown on a matrigel, while in vivo, a galectin-3-loaded matrigel was able to induce
angiogenesis in nude mice. Both of these processes relied on its CRD (83). Markowska et
al. later proposed that galectin-3 modulated VEGF and FGF-2-mediated angiogenesis by
activating focal adhesion kinase-mediated signalling pathways that modulate endothelial
cell migration during this process (84). The protein has also been linked to angiogenesis
and the migration of endothelial cells through integrin-linked kinase signalling (85).
Galectin-3 was also shown to bind to vascular endothelial growth factor receptor 2
(VEGFR2), promoting its phosphorylation and preventing its internalization, leading to
an increased angiogenic response of human umbilical cord endothelial cells to VEGFA in
vitro (86).
In combination with galectin-1, galectin-3 can activate and prevent the internalization of
VEGFR1, another process that enhances angiogenesis (85). Despite these findings, a
recent study in mice showed that during wound repair in skin, galectin-3 deficient mice
have no difference in vascular density or expression of angiogenic markers relative to
wild-type mice (87). These conflicting findings indicate that the role of galectin-3 in
angiogenesis likely tissue and context-dependant (64).

1.3.4

Role in Re-epithelialization

The first association of galectin-3 with re-epithelialization came from Kasper and Hughes
who noted the surface expression of galectin-3 in Type I and II alveolar epithelial cells in
a model of irradiation-induced lung inflammation and repair (88). In a model of corneal
wound healing, galectin-3 deficient mice were found to exhibit reduced reepithelialization rates relative to wild-type counterparts. Interestingly, galectin-3 did not
alter proliferation rates of epithelial cells and elevated levels of galectin-3 were detected
in the migrating epithelial front following injury, suggesting the protein promotes
epithelial cell migration (89). This was supported by later studies showing that galectin-3
promotes cell scattering, lamellipodia formation, and motility in human corneal epithelial
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cells (90). Furthermore, studies in mouse corneas showed that galectin-3 knockout mice
exhibit impaired re-epithelialization (89). The effect of the addition of exogenous
galectin-3 has also been investigated in models of murine corneal healing, where the
addition of exogenous galectin-3 increased re-epithelialization in wild type (WT) mice,
but not galectin-3 deficient mice (89). The increase in re-epithelialization in WT mice
was attributed to the modulation of galectin-7 by exogenous galectin-3, as galectin-7 was
found to accelerate re-epithelialization in galectin-3 knockout mice and because mouse
embryonic fibroblasts from galectin-3 knockout mice showed reduced levels of galectin-7
(89). Studies of epithelial wounds in monkey corneal explants also demonstrated
enhanced re-epithelization when recombinant human galectin-3 was added exogenously
to the media (91).
Consistent with studies in the cornea, studies in skin have revealed that keratinocytes
from galectin-3 knockout mice exhibit a migratory defect (75), and that reepithelialization is delayed in galectin-3 deficient mice (75, 87). However, in skin this
defect was attributed to deficient EGFR endocytosis and recycling, which is controlled by
cytosolic galectin-3 binding to ALG-2 interacting protein X (ALIX) (75). Additionally,
there were no differences between levels of galectin-7 in wound tissue from WT and
knockout mice at day 7 post injury, during which re-epithelialization was impaired (87).
Taken together, galectin-3 has been implicated in several processes associated with
wound

healing,

including

modulating

inflammation

and

contributing

to

re-

epithelialization. As a result, delivery of this protein during the wound healing process,
either topically or via a scaffold, is a potential new therapeutic to enhance repair.

1.4 Protein Delivery Strategy
1.4.1

Scaffolds for Protein Delivery

Although several growth factors and peptides have demonstrated therapeutic potential for
chronic wound healing, the effectiveness of applying such treatments topically is limited,
due to the peptidase-rich wound microenvironment, which impairs the bioactivity of
peptides, and the short half-life of both peptides and growth factors (92, 93). The use of
scaffolds for delivery of therapeutic agents aims to overcome this challenge. A scaffold is
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a three-dimensional polymeric structure used to treat a defect by acting as an artificial
ECM to guide regeneration (94). Their use in the delivery of bioactive molecules offers
several advantages, including protecting peptides from rapid biodegradation, providing a
large surface area to enable the effective delivery of bioactive molecules, and controlling
the release of bioactive molecules so that signals are provided continuously throughout
healing (93, 95). Using this method of delivery, the therapeutic agent is able to recruit
progenitor cells to the defect and guide cell behavior towards a pro-regenerative response
(95). Meanwhile, the scaffold nanotopography is also important in this process, providing
a site for cell adhesion and supporting cell proliferation and migration (96-99). Through
selection of appropriate therapeutic agents and appropriate scaffold design it is intended
that the application of a scaffold to a chronic wound microenvironment will be able to
achieve healing by stimulating a pro-regenerative response.

1.4.2

Scaffold Design for Tissue Regeneration

The overall aim in scaffold fabrication is to design an artificial matrix that closely mimics
the ECM of the immature granulation tissue (94). Within skin, the dermis consists largely
of collagen and contains a meshwork of fibers within the range of 30-130 nm (100). This
ECM is responsible for providing mechanical support as well as modulating cell
proliferation, migration, differentiation and apoptosis (100). Therefore it is ideal that a
scaffold contains fibers with diameters within this range. A high porosity is also needed
to support cell ingrowth and to facilitate the diffusion of waste and nutrients (101).
Several electrospun scaffolds have been able to obtain porosity values between 60-90%,
although 90% porosity has been suggested to be an ideal target (96, 101-103). Scaffolds
having pore sizes of approximately 100 μm and porosity in the 90% range have shown
the ability to support the infiltration of cells beyond the surface of the scaffold (104).
These considerations ensure a high surface area to volume ratio which can accommodate
high cell densities (100). Through selection and optimization of scaffold materials, it
should also be ensured that the rate of scaffold degradation coincides with the rate of
tissue regeneration. Finally, the material itself, along with degradation products, must be
biocompatible to ensure it will not elicit an immune response within the host tissue (100).
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1.4.3

Scaffold Materials

Scaffolds can be fabricated from a wide range of materials that include natural polymers,
synthetic polymers, and polymer composites. Naturally derived polymers commonly used
in wound healing include collagen, gelatin, chitosan, and silk fibroin (105). Currently, the
majority of artificially made skin substitutes approved for clinical use are collagen-based
scaffolds. These scaffolds typically consist of Type I collagen as it is the predominant
component of the dermal ECM (105). The use of collagen in scaffolds is advantageous as
it can regulate the adhesion, migration, proliferation, differentiation and survival of cells
(106). One limitation to collagen scaffold fabrication is that pure collagen is relatively
expensive (107). The processing of collagen during scaffold fabrication can also alter its
biological and structural properties (108). For example, Zeugolis et al. found that the
electrospinning of collagen resulted in its denaturation (109). Alteration of collagen
structure can also be caused by many sterilization methods (106). Gelatin is a denatured
form of collagen, which can be obtained through both alkaline or acid processing of
collagen (106). Use of gelatin for scaffold fabrication is desirable, as it maintains the
composition and properties of collagen, while also being commercially available at a low
cost (108, 110). Conversion of collagen to gelatin increases exposure of RGD sequences,
which may increase cell signaling (111). The use of electrospun gelatin scaffolds has
been shown to facilitate the adhesion, migration and proliferation of wound healing cell
types, and to increase wound closure in a full thickness wound model in rats (96-99).
Overall, natural polymers are strong candidates for wound healing applications as they
are biodegradable and biocompatible, supporting cell viability; however, they require
crosslinking to control their rate of degradation and mechanical properties (106, 108).
Synthetic polymers include poly-lactic acid (PLA), polycaprolactone (PCL) and polyglycolic acid (PGLA). There are several advantages for the use of synthetic polymers in
scaffold fabrication. They are well defined in structure, therefore there is no variation
between batches and fine tuning of both their mechanical properties and degradation
kinetics can be conducted to suit their application. They can also be supplied in large
quantities and are typically less expensive than natural polymers (112). However, cell
viability decreases when synthetic polymers are used as these materials have hydrophobic

25

surfaces, lack the appropriate cell recognition sites and have lower rates of cell adhesion
and proliferation (105, 107, 112, 113). To overcome these challenges, researchers are
attempting to improve the adhesive properties of these scaffolds by incorporating proteins
and amino acids including arginine-glycine-asparagine (RGD) sequences, cysteine,
lysine, laminin, and collagen-like proteins (114).
The use of polymer composites aims to overcome the limitations of both natural and
synthetic polymers to ultimately create scaffolds with the appropriate biocompatibility as
well as physical, mechanical, and chemical properties (107). In this method, a natural
polymer, such as collagen, gelatin, or chitosan can be blended with a synthetic polymer
such as PCL. This is done at an optimized concentration to improve the mechanical
stability using the synthetic component, while also improving the biocompatibility by
increasing hydrophilicity and by providing integrin binding sites through the natural
component (115, 116). This method also eliminates the need for pre-treatment of the
scaffolds to improve functionality (116). Blends of PCL/collagen were found to have
more stability relative to collagen-only scaffolds, while also having higher cell
proliferation than PCL alone (117). Blends of poly(L-lactic acid)-co-poly(ε-caprolactone)
(PLACL)/gelatin have also shown significantly higher proliferation of cells relative to
PLACL blends after 6 days in culture (115).

1.4.4

Scaffold Fabrication Methods

Several techniques are currently used for the fabrication of scaffolds in skin regeneration.
Freeze-drying, or lyophilization, is a process in which water is used to create porous
hydrogels (105). The process involves freezing a solution at a temperature between -70°C
and -80°C, followed by application of a partial vacuum to lower the pressure so that ice
can be removed from the material through sublimation. Unfrozen water is them removed
by desorption (118). This method is advantageous due to its use of water rather than
organic solvents during the fabrication process (118). The procedure can also be modified
to control the pore size and scaffold morphology (105). Decreasing the freezing rate has
been associated with increasing the resulting pore sizes in the fabrication of plant-derived
collagen sponges (119). In the lyophilization of gelatin, increasing the concentration of
gelatin can decrease the pore size, while increasing the freezing temperature creates
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larger mean pore sizes. Pore arrangement in parallel sheets can also be achieved by
conducting freezing at -196°C in liquid nitrogen (105). Although a simple technique,
freeze-drying is expensive and typically requires longer processing times than other
fabrication methods. Scaffold porosity is also often irregular and the surface is typically
dense, hindering cell migration into the inner areas of the scaffold (120, 121). Surface
skin, which is the collapsing of the material’s internal pores due to lack of structural
integrity, can also occur during the freeze-drying process if the freezing temperature is
too high (105).
Gas foaming is a technique in which a foaming agent such as sodium bicarbonate is
added to a hydrogel to create an inert gas, typically N2 or CO2. The pores are generated
from subsequent removal of the gas phase from the polymer and surfactants are typically
added to stabilize the foam that is created during the separation process (122). Using this
technique, the pore size and morphology of the scaffold can be modified by adjusting the
temperature and pressure during the procedure (105). Several other advantages include
the ability of this method to achieve high scaffold porosities and that the technique can be
conducted without the use of an organic solvent, enabling the incorporation of bioactive
molecules without their degradation (105, 121). However, the use of surfactant in this
method has the potential to negatively impact scaffold biocompatibility (122).
Solvent casting/ particle leaching is another scaffold fabrication method in which a
porogen, commonly sodium chloride, is added to a polymer solution that is placed into a
mould. The porogen is subsequently leached or removed through application of the
appropriate solvent (105). The pore sizes can be easily controlled by modifying the
particle size of the porogen (105). The mechanical strength of the scaffolds, rate of
biodegredation and porosity of the scaffolds can also be easily modified by adjusting the
concentration of the porogen (120). One drawback of this process is that longer
processing times are required due to the leaching step (121). The width of the scaffold is
also limited as it is difficult to remove the salt particles from the center of the material.
Thus, as the thickness increases, residual salt particles may remain within the material
(105). Another limitation of the salt/leaching method is that the leaching process often
requires the use of organic solvents which could negatively impact cell viability (105).
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While the aforementioned methods have their merits, electrospinning was the method of
choice due to the numerous advantages discussed below. In the electrospinning method, a
polymer solution is passed through a needle using an applied force from a syringe pump.
An electric potential is applied to the needle through which the polymer solution passes
such that as each droplet accumulates at the tip of the needle, it experiences electrostatic
repulsion between the surface charges of the droplet and Columbic force exerted by the
applied electric field (100). As charge accumulates on the surface of the droplet, a Taylor
cone is formed (100). Once the electrostatic charge exceeds the surface tension of the
polymer solution, a polymer jet is expelled and travels towards a grounded mandrel
(108). During this process, the solvent becomes evaporated, leaving dried fibers
deposited on the mandrel (105).
The use of electrospinning as a technique for creating scaffolds with nanotapographies
offers several advantages. Firstly, the electrospinning apparatus requires a minimal
amount of specialized equipment and is inexpensive relative to other technologies to set
up and operate (107, 108). The simplicity of the technique also makes it ideal for scale-up
and large-scale production (108). The technique is versatile, enabling it to be used for
many types of polymer and solvent systems. In fact, over 100 types of natural and
synthetic polymers have been electrospun with success (123). The properties of the
resulting fiber mats can also be tuned for the desired application. For example, the size
and shape of the scaffold can be varied through changing the collector substrate, and the
thickness of the scaffolds can be adjusted by changing the volume of the polymer
solution that is electrospun (100, 108). Parameters can also be modified to produce mats
with fibers that are randomly dispersed or aligned in uniaxial arrays (100, 123).
Furthermore, the resulting matrices are highly porous, having large surface area to
volume ratios, making them ideal for cell attachment and the exchange of nutrients and
waste (107, 123). Finally, the fibers can also be used for the encapsulation of ECM
proteins, enzymes, and growth factors (123).
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1.4.5

The Addition of Bioactive Compounds to Electrospun
Scaffolds

A simple approach for loading bioactive molecules into electrospun scaffolds is to use the
blend electrospinning method. In this method, the bioactive molecules are simply mixed
in the polymer solution prior to electrospinning. The resulting fibers have the bioactive
molecules dispersed within them enabling a more controlled release relative to the
physical adsorption of the molecules onto the scaffold surface. Using this method, there
is typically an initial burst release in vivo followed by a sustained release caused by
diffusion of the bioactive molecule and degradation of the polymer (95).
Several groups have used blend electrospinning with success, creating scaffolds for the
release of ECM proteins, peptides and growth factors while retaining bioactivity. Several
growth factors important to the wound healing process, including VEGF, PDGF, FGF
have been incorporated into scaffolds and have demonstrated support of the growth and
proliferation of cell types including keratinocytes, fibroblasts and endothelial cells (124,
125). Bertoncelj et al. demonstrated that platelet rich plasma, which is known to be
abundant in different growth factor types, can be delivered using chitosan/polyethylene
oxide scaffolds, stimulating proliferation of keratinocytes and fibroblasts in vitro (126).
Polyvinyl alcohol scaffolds have also been developed for the delivery of antifungal
peptide Cm-p1 (127). Our group has previously shown that type I collagen scaffolds
loaded with the matricellular protein periostin are able to recover alpha-smooth muscle
actin expression in wounds of periostin knockout mice (128). Another group developed
silk fibroin/gelatin scaffolds loaded with astragaloside IV, a natural herb. When tested in
vivo, the scaffolds were able to accelerate healing and prevented scar formation by
stimulating wound closure in partial thickness burn wounds in rats (129). Neurotensinloaded collagen scaffolds have also been shown to reduce inflammation and improve
wound closure in streptozotocin-induced diabetic mice (93). More complex blends of
bioactive compounds have also been incorporated into scaffolds. Peh et al. incorporated
vitamin C, fat soluble vitamin D3, hydrocortisone, insulin, triiodothyronine, and EGF
into poly (lactic-co-glycolic acid)/collagen scaffolds without loss of bioactivity. The
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resulting scaffolds were able to induce proliferation of keratinocytes and fibroblasts in
vitro (130).

1.5 Hypothesis and Objectives
1.5.1

Rationale

The electrospinning method can generate both collagen and gelatin fibers ranging from
50-500 nm, providing a biocompatible matrix of fibers within range of the native tissue
collagen fibrils (116, 131-134). The use of gelatin in electrospinning is preferable, as it is
similar in structure to collagen, which accounts for 70-80% of the skin’s dry weight,
while being considerably less expensive (135). Electrospun scaffolds have been
successful in supporting cell behaviour such as adhesion, proliferation and scaffold
infiltration as well as demonstrating enhanced wound closure kinetics in mouse
excisional wound healing models (96-99). In addition to acting as a matrix for cell
infiltration, scaffolds can also be used as delivery vehicles for growth factors and ECM
proteins in order to stimulate certain cellular behaviours and responses (128, 130, 136,
137). In this work, a nanofibrous gelatin scaffold will be fabricated for the purpose of
delivering exogenous galectin-3.
The addition of exogenous galectin-3 in a model of impaired wound healing has not yet
been investigated in skin. Previous studies have shown that galectin-3 knock-out mice do
not exhibit altered wound closure kinetics (87), although models of both corneal and skin
wound healing reveal that galectin-3 deficient mice exhibit delayed re-epithelialization
(75, 87, 89). Despite unaltered wound closure kinetics in galectin-3 knockout mice,
studies in mouse and monkey corneas reveal that the addition of exogenous galectin-3
enhances wound re-epithelialization in WT mice (89, 91). Whether galectin-3 has a
similar effect in WT mice in skin is unknown. Moreover, whether it could represent a
therapeutic for reversing impaired wound healing has not yet been tested.
Macrophages play a critical role in regulating the inflammatory phase of wound healing.
Classically activated macrophages, defined by their secretion of nitric oxide and proinflammatory cytokines, such as TNF-α, IL-6 and IL-12, exhibit pro-inflammatory
properties, while alternatively activated macrophages, defined by stimulation by IL-4 and
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IL-13 have the ability to control inflammation (8). Galectin-3 has previously been shown
to regulate alternative macrophage activation in vitro, with galectin-3 deficient cells
showing reduced levels of arginase I (63), therefore it will be interesting to determine
how delivery of exogenous galectin-3 via a gelatin scaffold will influence macrophage
polarization relative to a gelatin scaffold.

1.5.2

Hypothesis

We hypothesize that local delivery of galectin-3 either topically or using a gelatin
scaffold will accelerate skin wound closure in WT and db/db mice relative to empty
wounds. We secondarily hypothesize that the delivery of galectin-3 either topically or
using a gelatin scaffold will increase re-epithelialization and modulate inflammation by
stimulating M2 macrophage polarization.

1.5.3

Objectives

The objectives for this thesis were the following:
1. To develop a scaffold for the delivery of exogenous galectin-3
2. To evaluate the biocompatibility of the gelatin/galectin-3 scaffolds in vitro using
human dermal fibroblasts
3. To evaluate the effect of the gelatin/galectin-3 scaffold on wound healing in
murine models
a. Assess the influence of the scaffold on wound closure kinetics
b. Compare and contrast the efficacy of local delivery of topical galectin-3
versus gelatin/galectin-3 electrospun scaffolds on re-epithelialization and
macrophage polarization during skin healing.
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Chapter 2

2

The Influence of a Gelatin/Galectin-3 Scaffold on
Normal and Impaired Models of Skin Healing

2.1 Introduction
Normal skin healing involves a series of four overlapping phases: hemostasis,
inflammation, proliferation and remodeling (1). During healing, these processes occur in
a spatiotemporal manner to remove bacteria and damaged cells, restore the epithelial
barrier, as well as to synthesize and remodel the extracellular matrix at the site of injury,
restoring tissue function (2). Chronic wounds result when wounds fail to complete this
process and achieve healing, usually within twelve weeks of initial injury, resulting in
impaired tissue function and anatomy (3). The most common types of chronic wounds are
venous ulcers, arterial ulcers, pressure ulcers, and diabetic ulcers (3, 4). A variety of
factors can lead to their development, including vascular insufficiency, diabetes,
malnutrition, patient age, pressure, infection, and edema (5). These wounds become a
significant burden to the patient, as they can be painful, impair limb function, and result
in sepsis or the need for amputation (5). In addition, the burden to the Canadian
healthcare system is large, with the average cost of chronic wound treatment being
$10,376 (6).
Conventional treatment strategies involve removal of necrotic tissue, cleaning of the
wound, and use of antimicrobial agents to treat infection. Dressings can be applied to
retain moisture and promote healing, although their efficacy depends on specific wound
characteristics including the amount of exudate, depth and area of the wound, stage of
healing, and skin type of the patient (7, 8). Many adjunctive therapies are also available
for the treatment of chronic wounds including topical formulations, bioengineered skin
substitutes, hyperbaric oxygen therapy, and negative pressure wound therapy (8-12).
However, support for their use in this application is limited, as many treatments lack
multi-center studies that apply to broader patient populations and to non-healing chronic
wounds (11, 12). Therefore, new treatment strategies aimed at promoting healing in
chronic wounds are needed.
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When considering the development of new therapeutics for chronic skin wounds, it is
extremely important to factor in the underlying pathophysiology. Chronic wounds are
stalled in a deleterious pro- inflammatory state, with increased expression of
inflammatory cytokines such as interleukin-1 (IL-1), IL-6, and tissue necrosis factor
alpha (TNF-α), coupled with decreased levels of pro-regenerative cytokines including
transforming growth factor beta (TGF-β) and vascular endothelial growth factor (VEGF)
(13). Several molecular processes are known to exacerbate the inflammatory processes
and prevent progression into the proliferative phase of healing. The decreased levels of
growth factors, including keratinocyte growth factor, fibroblast growth factor 2 (FGF-2),
and VEGF, impede keratinocyte migration and granulation tissue formation (14, 15).
Additionally, there is an imbalance of proteolytic activity that leads to excessive
degradation of the extracellular matrix, inhibiting cell migration and proliferation (5, 15,
16). In diabetic patients, advanced glycation end products (AGEs) also accumulate due
to hyperglycemia (17) and can cause oxidative stress through interaction with AGE
receptors on macrophages and endothelial cells, triggering the release of proinflammatory cytokines (18). Considering the pathophysiology of chronic wounds,
therapeutic agents that can regulate inflammatory processes present an ideal treatment
strategy.
Galectin-3 is a protein implicated in the regulation of several processes required in
wound healing, particularly inflammation. Galectin-3 consists of a 120-amino acid Nterminal domain and a 130-amino acid carbohydrate recognition domain (CRD)
providing the capability to bind β-galactosides (19-21). In vitro, it has been shown to
increase migration of monocytes and macrophages (22). Additionally, galectin-3 has been
shown to link phagocytic macrophages to neutrophils as well as increase their neutrophil
uptake (23). This protein has also been associated with regulating alternative macrophage
activation, a process important in resolving inflammation (24). Studies in galectin-3
knockout mice have shown that re-epithelialization is impaired in both the cornea and in
skin, suggesting an important role for galectin-3 in re-epithelialization (25-27). In skin,
impaired re-epithelialization is attributed to deficient epidermal growth factor receptor
(EGFR) endocytosis and recycling, a process controlled by cytosolic galectin-3 binding
to ALG-2 interacting protein X (ALIX) (27). In the cornea, the addition of exogenous
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galectin-3 led to increased re-epithelialization, credited to its upregulation of galectin-7
which is decreased in mouse embryonic fibroblasts (25); however in skin, differences in
expression of galectin-7 in wound tissue are not observed concomitantly with impaired
re-epithelialization (26). The role of galectin-3 in promoting re-epithelialization and
modulating inflammation suggest that delivery of this protein to chronic wounds would
promote pro-regenerative processes. Therefore, investigation of this protein as a potential
therapeutic agent is needed.
Several groups have previously shown that growth factors, bioactive peptides,
matricellular proteins, and combinations thereof can be incorporated into scaffolds, while
exhibiting biological activity either in vitro or in vivo (28-31). Electrospinning is a
versatile technique for scaffold fabrication that can be fine-tuned to produce highly
porous fiber mats with large surface area to volume ratios (32, 33). Delivery of human
recombinant galectin-3 via an electrospun scaffold in wound healing is of interest, as the
scaffold would provide a large surface area, enabling effective delivery and distribution
of the protein in the wound bed to ensure that signals are provided continuously
throughout healing (20). In addition, the scaffold would act as an artificial extracellular
matrix, guiding regeneration by providing a site for cell adhesion and supporting the
proliferation and migration of cells into the wound bed (34-37).
The aim of this study was to fabricate a gelatin scaffold for the delivery of recombinant
human galectin-3 using the blend electrospinning method, to test its biocompatibility in
vitro and to test its efficacy in dermal wound healing in vivo. The adhesion, proliferation
and secretion of extracellular matrix proteins by human dermal fibroblasts on
gelatin/galectin-3 scaffolds were assessed in comparison to gelatin scaffolds. The
influence of the gelatin/galectin-3 scaffold in wound healing was then evaluated.
Evaluation was based on its effect on wound closure kinetics, re-epithelialization and
macrophage populations in vivo relative to treatment with topical galectin-3 and gelatin
scaffolds.
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2.2 Materials and Methods
2.2.1 Electrospinning
As shown in Figure 2.1, a polymer solution consisting of Type B Bovine gelatin (SigmaAldrich, St. Louis, MO, USA) dissolved in 40% v/v acetic acid (Thermo Fisher
Scientific, Waltham, MA, USA) was passed through a plastic 1cc syringe (Terumo,
Shibuya, Tokyo, Japan) and 20 gauge blunt-tip stainless steel needle using a syringe
pump (VWR International, Radnor, PA, USA). The needle was connected to a high
voltage DC power supply (Gamma High Voltage Research, Ormond Beach, FL, USA)
and a grounded stainless steel rotating mandrel. The mandrel speed was held constant at
100 revolutions per minute (RPM). The gelatin concentration, flowrate and collector
distance were varied as outlined in Table 1.
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Table 1: A summary of parameter combinations used during electrospinning to
compare the effects of the flowrate and collector distance on the resulting fiber
diameter
Concentration of Gelatin
(% Weight)
20
20
20
20
20
20
20
20
20
25
30

Flowrate
(mL/h)
0.1
0.1
0.1
0.3
0.3
0.3
0.5
0.5
0.5
0.5
0.5

Collector Distance
(cm)
6
10
14
6
10
14
6
10
14
10
10
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To fabricate each gelatin/galectin-3 scaffold, 5 μL of a 1 mg/mL solution of recombinant
human galectin-3 (R&D Systems, Minneapolis, MN, USA) in phosphate buffered saline
(PBS) was added to 0.75 mL of the polymer solution (gelatin and acetic acid) for a final
concentration of 6.7 μg/mL. Low concentration gelatin/galectin-3 scaffolds were
fabricated using a 0.5 mg/mL solution of galectin-3 in PBS, resulting in a final
concentration of 3.3 μg/mL. In gelatin scaffolds, 5 μL of PBS was added to the
electrospinning solution. Scaffolds were produced by electrospinning for 1.5 hours using
a total volume of 0.75 mL of each solution. Scaffolds were then crosslinked in a glass
desiccator (VWR International) containing drierite (W.A. Hammond Drierite Co. Ltd,
Xenia, OH, USA) using the vapour from a 5 mL solution consisting of 1.5% v/v
glutaraldehyde (GTA) (Sigma-Aldrich, St. Louis, MO, USA) in anhydrous ethyl alcohol
(Commercial Alcohols, Brampton, ON), similar to the methods of Zha et al. (37). The
desiccator was held under vacuum for 20 minutes and scaffolds were left in the sealed
desiccator for 48h to ensure sufficient crosslinking had taken place.

Following

crosslinking, scaffolds were stored in separate sealed plastic containers with desiccant at
2-8°C.
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Figure 2.1 – Schematic representation of the electrospinning process: A syringe
pump is used to feed the polymer solution through a 1cc syringe and 20 gauge needle at
the desired flowrate (0.1-0.5 mL/h). The needle is connected to a power supply and
grounded collector, creating an electric potential of 15 kV. Fibers are collected on a
rotating mandrel collector positioned 6-10 cm away from the tip of the needle.
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2.2.2 Assessment of Fiber Morphology
Three separate scaffolds (N=3) were electrospun at each set of conditions listed in Table
1. One circular sample (8 mm diameter) of as-spun fibers was collected per scaffold
using a biopsy punch (Integra Miltex,York, PA, USA). Samples were mounted on
aluminum stubs and sputter coated with osmium. Images were taken for each sample
using a scanning electron microscope (LEO 1530; Carl Zeiss, Oberkochen, Germany) at
2 kV and one of three magnifications: 1000X, 3000X, or 5000X. Using ImageJ software
(National Institutes of Health, Bethesda, MD, USA), the diameter of 250 fibers (N=3),
were measured from 5 separate images taken at the same magnification.

2.2.3 Mercury Porosimetry
Mercury porosimetry was used to assess the porosity of the refined gelatin scaffolds. For
each test, two scaffolds were electrospun from the same polymer solution for 1.5 hours
using the parameters outlined in Table 1. The scaffolds were subsequently crosslinked for
48 hours in 1.5% GTA vapour as previously described. Both scaffolds, measuring
approximately 4 x 10 cm were then removed from the aluminum foil, folded and placed
together in a 5cc stem which was loaded into the AutoPore IV 9500 mercury porosimeter
(Micrometrics Instrument Corp., Norcross, GA, U.S.A). The porosimeter generated a
pore size distribution, calculated the scaffold porosity and calculated the average pore
diameter (pore size) of the scaffolds.

2.2.4 Mass Spectrometry
Mass spectrometry was used to validate the presence of galectin-3 within the scaffold.
Prior to conducting mass spectrometry, three gelatin/galectin-3 scaffolds (6.7 μg/mL)
were blend electrospun and crosslinked as described in section 2.2.1. One piece of each
scaffold measuring approximately 9 cm2 was cut from each scaffold for mass
spectrometry. Each sample was then processed and mass spectrometry was conducted
according to the methods described by Moffe et al. (38). Processing of samples and mass
spectrometry were conducted by the Siqueira Laboratory.
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2.2.5 Scaffold Preparation for Cell Culture and Animal Studies
Prior to cell culture studies, scaffolds were removed from the sealed plastic containers
and each scaffold was quenched in 50 mL of 0.1 M glycine (Sigma-Aldrich) for 1 hour to
remove residual glutaraldehyde. Following quenching, three, 15 minute PBS rinses were
conducted and the scaffolds were left in PBS at 4°C overnight. For sterilization, scaffolds
were placed under ultra violet (UV) light for 60 minutes.

2.2.6 Adhesion Assay
Scaffolds were punched into circular samples using a 6 mm diameter biopsy punch and
placed into a 96-well cell culture plate (BD FalconTM, Franklin Lakes, NJ). Cells were
suspended in serum free Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Carlsbad,
CA, USA) supplemented with 1% antibiotic-antimicotic (AA) (100 U/mL penicillin, 100
μg/mL streptomycin and 0.25 μg/mL amphotericin B; Gibco) and seeded at a
concentration of 2.5 x 104 cells/mL. One hour following seeding, the media was removed
and wells were rinsed three times with PBS (Gibco) to remove non-adherent cells and
residual media. Scaffolds were transferred to a 500 μL microcentrifuge tube (Port City
Diagnostics, Wilmington, NC, USA) and both scaffolds and 96-well plates were stored at
-80°C until assayed. A cell pellet containing 2 x 105 cells was also frozen at -80°C to
generate the standard curve.
Adhesion, measured as cell number attached to the scaffolds, was quantified using the
CyQUANT® Proliferation Assay Kit (Molecular Probes, Carlsbad, CA, USA). Briefly,
samples were thawed at room temperature, and 200 μL of CyQUANT® GR dye/cell lysis
buffer was added to each microcentrifuge tube or well of the 96-well plate for 5 minutes
at room temperature while subjected to vortexing. Samples were covered in aluminum
foil during incubation. The supernatant from each sample was collected and transferred to
a flat-bottom, black 96-well microplate. Serial dilutions of the cell pellet in CyQUANT®
GR dye/cell lysis buffer were also transferred to the 96-well microplate to create a
standard curve (Appendix A). Fluorescence of each sample was measured using a Safire2
microplate reader (Tecan, Männedorf, Switzerland) at an excitation wavelength of 480
nm and an emission wavelength of 520 nm.
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2.2.7 Proliferation Assay
Scaffolds were punched into circular samples using a 6 mm diameter biopsy punch and
placed into a 96-well cell culture plate (BD FalconTM). Human dermal fibroblasts were
seeded into wells at a density of 3.3 x 103 cells/mL and were cultured for 1, 7, 10 or 14
days in DMEM (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco) and
1% AA. Split media changes were performed (75 μL) every 2 days. At each experimental
time point, the media was removed and wells were rinsed three times with PBS to remove
non-adherent cells and residual media. Scaffolds were transferred to 500 μL
microcentrifuge tubes and both scaffolds and 96-well plates were stored at -80°C until
assayed. A cell pellet containing 2 x 105 cells was also frozen at -80°C. The cell number
at each timepoint was determined using the CyQUANT® proliferation assay kit as
described in section 2.2.6 and the standard curve is shown in Appendix A.

2.2.8 Extracellular Matrix Deposition Studies
Scaffolds were punched into circular samples using a 6 mm diameter biopsy punch and
placed into a 96-well cell culture plate (BD FalconTM). Human dermal fibroblasts were
seeded into wells at a density of 3.3 x 104 cells/mL and were cultured for 3 and 7 days in
DMEM supplemented with 10% FBS (Gibco), 1 % AA and 50 μg/mL ascorbic acid.
Media was changed every 2 days. At each experimental timepoint, cells were fixed in 4%
paraformaldehyde (PFA) in PBS for 5 minutes. Three rinses with PBS were conducted
followed by treatment with 0.1% Triton X-100 in PBS for 5 minutes to permeabilize the
cell membranes. Cells were rinsed again in PBS three times, followed by blocking with
1% bovine serum albumin (BSA) in PBS at 4°C overnight. Scaffolds were incubated with
primary antibodies against fibronectin (sc-8422; Santa Cruz Biotechnology, Dallas, TX,
USA) diluted at 1:100 in 1% BSA in PBS for one hour at room temperature and were
rinsed three times with PBS for 5 minutes. Scaffolds were incubated for 90 minutes at
room temperature with Indodicarbocyanine (Cy5) Goat Anti-Mouse IgG antibody
(Jackson Immuno Research Laboratories, West Grove, PA, USA) at a 1:200 dilution and
rhodamine-conjugated phalloidin (Molecular Probes) at a 1:100 dilution. Negative
controls were prepared without the addition of the primary antibody. Following
incubation, scaffolds were washed three times for 5 minutes in PBS and mounted on

54

glass coverslips using Vectashield Mounting Medium (Vector Laboratories) containing
4’, 6-diamidino-2-phenylindole (DAPI). Coverslips were sealed with clear nail enamel.
Samples were analyzed with an Axio Observer Z1 fluorescence microscope (Carl Zeiss)
using the appropriate filters. Negative controls were imaged to set the threshold values
for the detection of fluorescence (Appendix B).

2.2.9 Wound Closure Kinetics Study
All animal procedures were in compliance with protocols approved by the University
Council on Animal Care at Western University. Six diabetic (db/db) (B6.BK(D)
Leprdb/J; 000697) and six wild type (WT) (C57BL/6J; 000664) mice (The Jackson
Laboratory; Sacramento, CA) were used for experiments. All mice were age and sexmatched and were 11 weeks of age at the time of surgery. Prior to surgery, all mice were
given 0.05 mg/kg of buprenorphrine as a pre-emptive analgesic. Animals were then
anaesthetized using isoflurane, fur was removed from the surgical site and povidoneiodine was used to clean the area. Four full thickness wounds measuring 6 mm in
diameter were then created using a sterile biopsy punch.
For wound closure kinetics studies, each wound was assigned one of four treatment
conditions: empty (control wound), gelatin scaffold, a gelatin scaffold made using 3.3
μg/mL galectin-3 or a gelatin scaffold made using 6.7 μg/mL galectin-3 (N=6 wounds for
each treatment group). Treatments were rotated clockwise in each mouse to eliminate
positional effects on wound healing. Scaffolds measuring 8 mm in diameter and sterilized
under UV light for 60 minutes were then placed into the wounds. Mice were injected with
0.05 mg/kg of buprenorphrine again following surgery. On day 17 post-wounding, all
mice were euthanized using carbon dioxide exposure. Tissue samples of the wounds were
harvested immediately afterwards and were fixed in 10% neutral buffered formalin
(Sigma-Aldrich) for 24 hours at 4°C, transferred to 70% ethanol (Commercial Alcohols)
and were paraffin embedded. Serial 5 μm sections were taken from the center of the
wounds. To calculate wound closure kinetics, all mice were imaged using a digital
camera (Canon, Tokyo, Japan) on days 0, 3, 5, 7, 9, 11, 13, 15, and 17. A ruler was
included in each image so that the measurements of wound area could be standardized.
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Image J software (National Institutes of Health) was used to calculate the wounded area
at each time point (39).

2.2.10

Investigation of Re-Epithelialization and Macrophage
Polarization

All animal procedures were in compliance with protocols approved by the University
Council on Animal Care at Western University. Six db/db (B6.BK(D)Leprdb/J; 000697)
and six WT (C57BL/6J; 000664) mice were purchased from The Jackson Laboratory
(Sacramento, CA). All mice were age-matched and sex-matched and were 12 weeks of
age at the time of surgery. Prior to surgery, all mice were injected with 0.05 mg/kg of
buprenorphrine. Animals were then anaesthetized using isoflurane, fur was removed from
the surgical site and povidone-iodine was used to clean the area. Four full thickness
wounds measuring 6 mm in diameter were then created using a sterile biopsy punch.
Each wound was assigned one of four treatment conditions: empty (control wound),
topical galectin-3 (6.7 μL galectin-3 in sterile saline), gelatin scaffold, or a gelatin
scaffold containing 6.7 μg/mL galectin-3 (N=6 wounds for each treatment group).
Scaffolds measuring 8 mm in diameter and disinfected under UV light for 60 minutes
were then placed into the wounds. Topical galectin-3 was mixed with sterile saline at 6.7
μg/mL and 10 μL of this solution was added to the wound following the surgery and each
subsequent day until mice were euthanized. Mice were injected with 0.05 mg/kg of
buprenorphrine following surgery. Mice were euthanized using carbon dioxide exposure
on days 5 (N=3 WT mice; N=3 db/db mice) and 7 (N=3 WT mice; N=3 db/db mice) postwounding. Tissue samples of the wounds were harvested immediately afterwards and
were fixed in 10% neutral buffered formalin (Sigma-Aldrich) for 24 hours at 4°C,
transferred to 70% ethanol (Commercial Alcohols) and were paraffin embedded. Serial 5
μm sections were taken from the center of the wounds.
To calculate wound closure kinetics, all mice were imaged on 0, 3, 5, and 7 days. A ruler
was included in each image so that the measurements of wound area could be
standardized. Image J software (National Institutes of Health) was used to calculate the
wounded area at each time point (39).
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Masson’s Trichrome staining, conducted by the Pathology department within the London
Health Sciences Centre, was used to visualize collagen deposition and reepithelialization. Sections were imaged with a Leica DM100 light microscope (Leica,
Wetzlar, Germany). Analysis was conducted on Masson’s Trichrome stained sections
using ImageJ software (National Institutes of Health) to measure the length of the
epithelial tongue and the thickness of the epithelium (26, 39).
Immunohistochemical staining for inducible nitric oxide synthase (iNOS) and arginase I
was performed to visualize M1 and M2 macrophage populations. Sections were
rehydrated, rinsed with PBS for 5 minutes and subjected to enzymatic antigen retrieval
for 15 minutes at 37°C. Samples were rinsed again in PBS for 5 minutes at room
temperature and blocked using 10% horse serum in PBS for 30 minutes at room
temperature in a humidified chamber. Sections were then incubated in primary goat
antibodies against arginase I (sc-18354; Santa Cruz Biotechnology) diluted at 1:100 in
10% horse serum and rabbit antibodies against iNOS (ab3523; Abcam, Cambridge, UK)
diluted at 1:25 in 10% horse serum overnight at 4°C. Sections were rinsed in PBS and
incubated with secondary antibodies at a dilution of 1:500 in horse serum for one hour at
room temperature, while protected from light. Antibodies included an Alexa Fluor 647
anti-rabbit antibody (Abcam) and an Alexa Fluor 488 anti-goat antibody (Abcam).
Hoechst 33342 (Trihydrochloride Trihydrate; Thermo Fisher Scientific) was also added
at a dilution of 1:1000. Sections were rinsed in PBS to remove unbound antibodies and
were mounted using Immuno-Mount (Thermo Fisher Scientific) mounting medium.
Coverslips were sealed with clear nail enamel. Sections were imaged using an Axio
Observer Z1 fluorescence microscope (Carl Zeiss) using the appropriate filters. Negative
controls were sectioned and stained without the addition of primary antibodies. These
negative control slides were imaged to set the threshold values for the detection of
fluorescence (Appendix C). ImageJ software was used to quantify the number of arginase
I-positive macrophages in the wound bed in WT mice at day 7 (N=3, n=3) (National
Institutes of Health).
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2.3 Results
2.3.1 Influence of Electrospinning Parameters on Fiber Diameter and
Scaffold Morphology
To determine the influence of electrospinning parameters on the resulting fiber diameter,
12 different parameters were assessed. The influence of three different concentrations of
gelatin, three solution flowrates, and three collector distances on fiber diameter were
investigated. In order to determine the influence of the flowrate and needle to collector
distances, these parameters were varied while the concentration of gelatin was held
constant at 20% weight. Statistical analysis revealed, at each flowrate assessed, there
were no significant differences in the fiber diameter when the collector distance was
increased (Figure 2.2; p>0.05). Additionally, at each collector distance, there were no
significant differences in the fiber diameter when the flowrate was increased (Figure 2.2;
p>0.05). To determine the influence of gelatin concentration on the resulting fiber
diameter, both the solution flowrate and the collector distance were held constant while
the gelatin concentration was increased. As the concentration of gelatin was increased,
the resulting fiber diameter increased. Scaffolds electrospun using a concentration of 30%
weight gelatin had a significantly larger mean fiber diameter than fibers electrospun using
20% weight and 25% weight gelatin (Figure 2.3; p<0.05). Differences in the mean fiber
diameter between 20% weight and 25% weight gelatin were not statistically significant.
Increases of fiber diameter corresponding to increases in gelatin concentration were also
apparent upon observation of the fiber diameter distributions (Figure 2.4G, H, I).
When 30% weight gelatin was used (Figure 2.4I), the majority of fibers were 500-1500
nm in diameter. There was a large variation in fiber size, with fibers measuring up to
4000 nm in diameter. At 25% weight, the majority of the fibers were within range of 300500 nm (Figure 2.4H). The distribution of fiber size was even smaller at 20% weight
gelatin, with the majority of fibers measuring between 100-200 nm (Figure 2.4I).
To determine whether the differences in fiber diameter were associated with
morphological changes in the fibers, fiber morphology was assessed in scanning electron
microscopy (SEM) images taken at each concentration of gelatin. At the 20% weight
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concentration of gelatin, SEM analysis revealed the presence of beaded fibers in the
electrospun fiber mat (Figure 2.4A, D). In the fibrous mats electrospun using a 25%
weight solution of gelatin, SEM showed that the mats contained various web-like and
ribbon-like fibers (Figure 2.4B and E). Scaffolds electrospun using 30% weight gelatin
consisted mainly of the ribbon-like fibers, although the relative abundance of cylindrical
and ribbon-like fibrils was not quantified (Figure 2.4C and F).
To determine whether increasing the gelatin concentration above 20% weight could
eliminate beaded fibers, while maintaining fiber diameters within the 100-200 nm range,
the gelatin concentration was increased to 21% weight and SEM was conducted to
determine the morphological characteristics as well as measure the resulting mean fiber
diameter. The resulting mean fiber diameter was 224.6 ± 13.39 nm and SEM revealed
that there were no beads within the fiber mat (Figure 2.5A). The frequency distribution
obtained from this sample revealed that fiber diameters ranged from roughly 100-300 nm
and fibers in the range of 230-250 nm were most frequently measured (Figure 2.5B).
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Figure 2.2 – Effect of increasing collector distance and flowrate on mean fiber
diameter: Fiber diameters measured at 9 combinations of flowrate and collector
distances. The flowrate was varied between 0.1, 0.3 and 0.5 mL/h and the collector
distance was varied between 6, 10 and 14 cm. The concentration of gelatin was held
constant at 20% weight. No significant differences in fiber diameter were observed at any
of the conditions assessed. N=3, n=250, two-way ANOVA, p>0.05. All data is
̅.
represented as mean ± SEM
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Figure 2.3 – Effect of increasing concentration on mean fiber diameter: Mean fiber
diameters measured at 20%, 25% and 30% weight gelatin. The flowrate and collector
distance were held constant at 0.5 mL/h and 10 cm, respectively. Fibers electrospun at a
concentration of 30% weight gelatin had significantly higher fiber diameters than those
electrospun at 25% weight and 20% weight gelatin. N=3, n=250, one-way ANOVA,
Tukey post-test for multiple comparisons, *p <0.05. All data is represented as mean ±
̅.
SEM
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Figure 2.4 – The effect of increasing concentration on fiber morphology and fiber
size distribution: A-F: Images of electrospun gelatin nanofibers collected by SEM. Fiber
mats were electrospun using a flowrate of 0.5 mL/h, collector distance of 10 cm and
varying gelatin concentrations. A-C: Images were taken at 1000x magnification. Scale
Bar: 25 μm. D-F: Images were taken at 5000x magnification. Scale Bar: 5 μm. G-I:
Frequency distribution graph showing the percentage of fiber diameters (from 750
measurements across N=3 experiments) within each bin range for scaffolds electrospun
using a flowrate of 0.5 mL/h, a collector distance of 10 cm, and a gelatin concentration of
20%, 25%, and 30% weight. N=3, n=250. G: Bin size: 20 nm. H: Bin size: 50 nm. I: Bin
size: 500 nm. At a concentration of 20% weight gelatin, beaded fibers are shown within
the fiber mat and the majority of fibers measured between 100-200 nm in diameter. At
25% weight gelatin, both ribbon-like and web-like fibers were detected in the fiber mat.
The majority of fibers measured between 200-500nm in diameter. At 30% weight gelatin,
the mat consisted mainly of ribbon-like fibers, the majority of which measured between
500-1500 nm.
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Figure 2.5 – Refined scaffold morphology and fiber size distribution: (A) SEM image
of a scaffold electrospun using a flowrate of 0.5 mL/h, a collector distance of 10 cm, and
a gelatin concentration of 21% weight. Scale Bar: 15 μm. (B) Frequency distribution
graph showing the percentage of fiber diameters within each bin range for scaffolds
electrospun using a flowrate of 0.5 mL/h, a collector distance of 10 cm, and a gelatin
concentration of 21% weight. N=3, n=250. Bin size: 20 nm.
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2.3.2 Scaffold Porosity is Sufficient for Cell Growth
Mercury porosimetry was conducted to evaluate scaffold porosity and to determine
whether scaffold pore sizes would be sufficient to allow cell infiltration. Analysis
revealed that scaffolds are 83.08 ± 4.06 % porous and have an average pore diameter of
1.15 ± 0.77 μm (N=3). A representative graph showing the pore size distribution is
shown in Figure 2.6. The scaffolds contain pores ranging from 0.1 to 100 μm in size, with
the majority of the pore diameters are observed within the range of 0.3-0.8 μm and 30-50
μm.
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Figure 2.6 – Mercury porosimetry pore size distribution plot: Representative graph of
pore diameter distribution measured as a function of differential and cumulative intrusion
volumes. The cumulative pore volume curve shows steeper slopes between 10-100 μm
and 0.1-1 μm, coinciding with peaks in the log differential intrusion volume. Each log
differential intrusion value represents the relative quantity of mercury entering pores of a
specific diameter. Mercury porosimetry was repeated three times (N=3) on different
batches of scaffolds.
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2.3.3 Detection of Galectin-3 in Scaffolds
To ensure the blend electrospinning method resulted in scaffolds containing recombinant
human galectin-3, mass spectrometry was conducted on crosslinked samples of scaffolds
electrospun with galectin-3. Table 2 summarizes the findings from the mass spectrometry
analysis. Four sequences from recombinant human galectin-3 were identified, verifying
its presence within the scaffolds. Identified sequences were run using the Basic Local
Alignment Search Tool (BLAST) in the Universal Protein Resource (UniProt) database
which showed that each detected sequence aligned to a specific sequence contained
within the CRD of human recombinant galectin-3 and matched with 100% sequence
identity (Figure 2.7).
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Table 2: Human recombinant galectin-3 amino acid sequences detected by mass
spectrometry
Accession
Number

Description

Sequences Detected

Sequence
Identity (%)

P17931

LEG3 HUMAN –
Galectin-3 Homo Sapiens
(Human)

MLITILGTVKPNANR

100

P17931

LEG3 HUMAN –
Galectin-3 Homo Sapiens
(Human)

GNDVAFHFNPR

100

P17931

LEG3 HUMAN –
Galectin-3 Homo Sapiens
(Human)

P17931

LEG3 HUMAN –
Galectin-3 Homo Sapiens
(Human)

IQVLVEPDHFK

VAVNDAHLLQYNHR

100

100
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Figure 2.7 – Visualization of detected sequences on recombinant human galectin-3:
Mass spectrometry was conducted three times for detection of galectin-3. Four peptide
sequences having 100% alignment with the human recombinant galectin-3 protein
structure in the carbohydrate recognition domain were detected. (A) 15 amino acid
sequence of MLITILGTVKPNANR aligns with the protein at amino acid locations 130144. (B) 11 amino acid sequence of GNDVAFHFNPR aligns with the protein at amino
acid locations 152-162. (C) 11 amino acid sequence of IQVLVEPDHFK aligns with the
protein at amino acid locations 200-210. (D) 14 amino acid sequence of
VAVNDAHLLQYNHR aligns with the protein at amino acid locations 211-225.
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2.3.4 Scaffolds Increase the Initial Adhesion of Human Dermal
Fibroblasts
Human dermal fibroblasts were seeded onto tissue culture plastic, gelatin scaffolds and
gelatin/galectin-3 scaffolds (6.7μg/mL). Cells adhered to all surfaces within one hour
(Figure 2.8). Significantly more cells were detected on gelatin scaffolds relative to the
tissue culture plastic (N=3, n=3, p<0.01). Similarly, significantly more cells attached to
gelatin/galectin-3 scaffolds than tissue culture plastic (N=3, n=3, p<0.001). However, no
significant differences in cell number were detected between the gelatin and
gelatin/galectin-3 scaffolds at one hour following seeding (N=3, n=3, p >0.05).

2.3.5 Scaffolds Support the Proliferation of Human Dermal
Fibroblasts
To assess increases in human dermal fibroblast numbers, cell numbers were quantified at
days 1, 7, 10, and 14 post-seeding. Cell numbers increased over a 14 day period when
cultured on tissue culture plastic, the gelatin scaffold and the gelatin/galectin-3 scaffold
(Figure 2.9). There were no significant differences in cell numbers between the three
conditions at each time point assessed (N=3, n=4, p >0.05).

2.3.6 Scaffolds Support the Production of Fibronectin by Human
Dermal Fibroblasts
Human dermal fibroblasts were cultured on both gelatin scaffolds and gelatin/galectin-3
scaffolds for up to 7 days to observe whether the scaffolds were able to support secretion
of fibronectin. Staining of the filamentous actin (red) demonstrated that the cells were
attached and well spread at days 3 and 7 post-seeding (Figure 2.10). Staining for
extracellular fibronectin revealed its deposition by fibroblasts on both gelatin and
gelatin/galectin-3 scaffolds at days 3 and 7 post-seeding (Figure 2.11). Increased
deposition was seen qualitatively on the scaffolds by day 7 although no observable
differences in the immunoreactivity for fibronectin was evident between the scaffolds at
both of the time points examined.
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Figure 2.8 – Adhesion of human dermal fibroblasts on scaffolds: Human dermal
fibroblasts were seeded onto tissue culture plastic, gelatin scaffolds and gelatin/galectin-3
scaffolds (6.7 μg/mL) and left to attach for one hour. At one hour following seeding, cell
numbers were significantly higher in wells containing the gelatin/galectin-3 scaffolds
than in tissue culture plastic wells. Cell numbers were also significantly higher in wells
containing the gelatin scaffolds than in tissue culture plastic wells. N=3, n=3, one-way
ANOVA, Tukey post-test for multiple comparisons, **p<0.01, ***p<0.001. All data is
̅.
represented as mean ± SEM
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Figure 2.9 – Proliferation of human dermal fibroblasts on scaffolds: Human dermal
fibroblasts were cultured on tissue culture plastic, gelatin scaffolds and gelatin/galectin-3
scaffolds (6.7 μg/mL) over 14 days. There were no significant differences in the cell
number between the groups at all time points assessed. N=3, n=4, two-way ANOVA,
̅.
p>0.05. All data is represented as mean ± SEM
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Figure 2.10 – Visualization of human dermal fibroblast cytoskeleton on scaffolds:
Human dermal fibroblasts were cultured on tissue culture plastic, gelatin and
gelatin/galectin-3 scaffolds (6.7μg/mL) over 7 days. Representative images show the cell
cytoskeleton (red) and cell nuclei (blue) using immunocytochemistry. Human dermal
fibroblasts cultured on scaffolds show appropriate fibroblast-like morphology and cell
spreading after 3 days in culture, consistent with the tissue culture plastic controls. Cells
remain spread along the scaffold surface after 7 days in culture. N=3, n=3, scale bar:
50μm.
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Figure 2.11 – Deposition of fibronectin by human dermal fibroblasts on scaffolds:
Human dermal fibroblasts were cultured on tissue culture plastic, gelatin and
gelatin/galectin-3 scaffolds (6.7 μg/mL) over 7 days. Representative images show
fibronectin (green) and cell nuclei (blue) using immunocytochemistry. Fibronectin was
detected after 3 days on the tissue culture plastic, gelatin and gelatin/galectin-3 scaffolds.
Fibronectin remained present at 7 days following seeding. There were no observable
differences in the amount of fibronectin deposited between the scaffolds. N=3, n=3, scale
bar: 50μm.

82

83

2.3.7 Gelatin/Galectin-3 Scaffolds Do Not Alter Skin Closure Kinetics
in Wild Type and Diabetic Mice
To determine whether gelatin/galectin-3 scaffolds influence wound closure kinetics in
WT mice, each of the four experimentally created wounds were given a different
treatment: a gelatin scaffold, a gelatin scaffold loaded with 3.3 μg/mL galectin-3, a
gelatin scaffold loaded with 6.7 μg/mL galectin-3 or no treatment (left empty).
Representative images of the wounds for each treatment are shown at day 0, day 9, and
day 17 in Figure 2.12. Wound closure rates were compared between wounds on days 3, 5,
7, 9, 11, 13, 15, and 17 following surgery (Figure 2.13). At day 7, statistical analysis
showed that wounds treated with the gelatin scaffolds had significantly higher wound
closure than wounds treated with gelatin/galectin-3 scaffolds (6.7 μg/mL) (p<0.05, N=6).
No statistical differences in wound closure were observed between the treatment groups
at all other time points assessed (p>0.05, N=6).
To determine whether gelatin/galectin-3 scaffolds influence wound closure kinetics in an
impaired model of wound healing, full thickness excisional wounds in db/db mice were
treated with the same four treatment groups as described for WT mice. Representative
images of the wounds for each treatment at day 0, day 9, and day 17 are shown in Figure
2.14. Wound closure was compared between wounds on days 3, 5, 7, 9, 11, 13, 15, and
17 following surgery (Figure 2.15). Statistical analysis showed that there were no
significant differences in wound closure between the treatment groups at all time points
assessed (p>0.05, N=6).
Masson’s trichrome staining in db/db mice revealed that wounds in each condition were
completely re-epithelialized by day 17 post-surgery (Figure 2.16). There were no
observable differences in the thickness of the epithelium or in the amount of collagen in
each of the conditions assessed. At day 17 in WT mice, the wounds had completely
closed and the mice had regained hair at the wound site making it difficult to identify the
original location of the wounds. Therefore, sectioning and staining was not conducted on
WT mice at day 17.
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Figure 2.12 – Representative images of the wound area for evaluation of wound
closure kinetics in WT mice: Full thickness excisional wounds measuring 6 mm in
diameter were treated with a gelatin scaffold, a gelatin/galectin-3 scaffold (3.3 μg/mL), a
gelatin/galectin-3 scaffold (6.7 μg/mL), or left empty (control). Representative images of
the four conditions from one WT mouse are shown at day 0, day 9 and day 17. Wounds
appear much smaller by day 9 in all treatment conditions and by day 17 wounds achieved
closure with hair returning to the wound site. N=6, scale bar = 2.5 mm.
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Figure 2.13 – Wound closure kinetics in vivo for full thickness wounding in WT
mice: Full thickness excisional wounds measuring 6 mm in diameter were treated with a
gelatin scaffold, a gelatin/galectin-3 scaffold loaded at 3.3 μg/mL, a gelatin/galectin-3
scaffold loaded at 6.7 μg/mL, or left empty (control). The percentage of closure relative
to the original wound was calculated over a 17 day period. There were no significant
differences between each of the treatment groups and the experimental control (empty
wound) at all time points assessed (p>0.05). Wound closure increased steadily over the
17 day period, with all wounds achieving closure by day 17. N=6, two-way ANOVA,
Tukey post-test for multiple comparisons, p>0.05 between each treatment and the control
̅.
scaffold. Data is represented as mean ± SEM
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Figure 2.14 – Representative images of the wound area for evaluation of wound
closure kinetics in db/db mice: Full thickness excisional wounds measuring 6 mm in
diameter were treated with a gelatin scaffold, a gelatin/galectin-3 scaffold (3.3 μg/mL), a
gelatin/galectin-3 scaffold (6.7 μg/mL), or left empty (control). Representative images of
the four treatment conditions from one db/db mouse are shown at day 0, day 9 and day
17. Wound size was decreased slightly by day 9 in all treatment conditions. At day 17
wounds were still visible. N=6, scale bar = 2.5 mm.
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Figure 2.15 – Wound closure kinetics in vivo for full thickness wounding in db/db
mice: Full thickness excisional wounds measuring 6 mm in diameter were treated with a
gelatin scaffold, a gelatin/galectin-3 scaffold loaded at 3.3 μg/mL, a gelatin/galectin-3
scaffold loaded at 6.7 μg/mL, or left empty (control). The percentage of closure relative
to the original wound was calculated over a 17 day period. There were no significant
differences between each of the treatment groups and the experimental control (empty
wound) at all time points assessed (p>0.05). Wound sizes initially increase in db/db
mice, with wound closure steadily increasing after day 9. N=6, two-way ANOVA, Tukey
post-test for multiple comparisons, p >0.05 between each treatment and the control
̅.
scaffold. Data is represented as mean ± SEM
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Figure 2.16 – Masson’s Trichrome staining at day 17 following in vivo full thickness
wounding in db/db mice: Representative images of the center of the wound bed for
db/db mice at 17 days post-wounding. Sections from all six mice were stained and
analyzed. (A) Empty wound. (B) Wound treated with gelatin scaffold. (C) Wound treated
with gelatin/galectin-3 scaffold (3.3 μg/mL). (D) Wound treated with gelatin/galectin-3
scaffold (6.7 μg/mL). Collagen content appeared similar in all conditions assessed at 17
days post-wounding. Wounds subjected to each treatment condition were fully reepithelialized by 17 days post-wounding. N=6, scale bar: 500μm.
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2.3.8 The Effect of Topical Galectin-3 and Gelatin/Galectin-3
Scaffolds on Re-Epithelialization in Wild-Type and Diabetic
Mice
To determine the effect of gelatin/galectin-3 scaffolds on re-epithelialization at earlier
time points, full thickness excisional wounds were created in WT and db/db mice and
received one of 4 treatments: control (empty), topical galectin-3 (6.7 μg/mL), a gelatin
scaffold, or a gelatin scaffold containing 6.7 μg/mL galectin-3. In WT mice, analysis
revealed that there were no significant differences in the percentage of wound closure
across the four treatment groups at 5 and 7 days post-wounding (N=3, p>0.05) (Figure
2.17A, B). At both days 5 and 7, there were also no significant differences in the
percentage of re-epithelialization (N=3, p>0.05) (Figure 2.17C, D) or the thickness of the
epithelium (N=3, p>0.05) between the treatments (Figure 2.17E, F). Masson’s Trichrome
staining of sections from each treatment group in WT mice at day 5 and day 7 are shown
in Figure 2.18.
In the db/db mice, analysis revealed that there were no significant differences in the
percentage of wound closure across the four treatment groups at 5 and 7 days post
wounding (N=3, p>0.05) (Figure 2.19A,B). At both days 5 and 7, there were no
significant differences in the percentage of re-epithelialization (N=3, p>0.05) (Figure
2.19C, D), or the thickness of the epithelium (N=3, p>0.05) (Figure 2.19E, F). Masson’s
Trichrome staining of sections from each treatment group in db/db mice at day 5 and day
7 are shown in Figure 2.20.
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Figure 2.17 – Wound closure, re-epithelialization and epithelial thickness in WT
mice: Full thickness excisional wounds measuring 6 mm in diameter were treated with
topical galectin-3 (6.7 μg/mL), a gelatin scaffold, a gelatin/galectin-3 scaffold (6.7
μg/mL), or left empty (control). (A, B) The percentage of closure relative to the original
wound was calculated at day 5 (N=3) and day 7 (N=3). There were no significant
differences in closure between each of the treatment groups at days 5 and 7. N=3, oneway ANOVA, Tukey post-test for multiple comparisons, p>0.05. (C, D) The percentage
of re-epithelialization was calculated at day 5 (N=3) and day 7 (N=3). There were no
significant differences in re-epithelialization between each of the treatment groups at
days 5 and 7. N=3, one-way ANOVA, Tukey post-test for multiple comparisons, p >0.05.
(E, F) The thickness of the epithelium was calculated at days 5 (N=3) and day 7 (N=3).
There were no significant differences in the epithelial thickness between each of the
treatment groups at days 5 and 7 following wounding. N=3, one-way ANOVA, Tukey
̅.
post-test for multiple comparisons, p>0.05. All data is represented as mean ± SEM
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Figure 2.18 – Masson’s Trichrome staining following in vivo full thickness wounding
in WT mice: Full thickness excisional wounds measuring 6 mm in diameter were treated
with topical galectin-3 (6.7 μg/mL), a gelatin scaffold, a gelatin/galectin-3 scaffold (6.7
μg/mL), or left empty (control). Sections show the wound edge for each condition and the
epithelial tongue. (A) Images shown of the four treatment conditions are from one mouse
at day 5 and one mouse at day 7. (B) Images shown of the four treatment conditions are
from a different mouse at day 5 and a different mouse at day 7 to show the variability
between mice. S=scaffold, N=3, scale bar: 500μm.
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Figure 2.19 – Wound closure, re-epithelialization and epithelial thickness in db/db
mice: Full thickness excisional wounds measuring 6 mm in diameter were treated with
topical galectin-3 (6.7 μg/mL), a gelatin scaffold, a gelatin/galectin-3 scaffold (6.7
μg/mL), or left empty (control). (A,B) The percentage of closure relative to the original
wound was calculated at days 5 (N=3) and day 7 (N=3). There were no significant
differences in closure between each of the treatment groups at days 5 and 7. N=3, oneway ANOVA, Tukey post-test for multiple comparisons, p>0.05. (C, D) The percentage
of re-epithelialization was calculated at days 5 (N=3) and day 7 (N=3). There were no
significant differences in re-epithelialization between each of the treatment groups at
days 5 and 7. N=3, one-way ANOVA, Tukey post-test for multiple comparisons, p>0.05.
(E, F) The thickness of the epithelium was calculated at days 5 (N=3) and day 7 (N=3).
There were no significant differences in the epithelial thickness between each of the
treatment groups at days 5 and 7. N=3, one-way ANOVA, Tukey post-test for multiple
̅.
comparisons, p>0.05. All data is represented as mean ± SEM
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Figure 2.20 – Masson’s Trichrome staining following in vivo full thickness wounding
in db/db mice: Full thickness excisional wounds measuring 6 mm in diameter were
treated with topical galectin-3 (6.7 μg/mL), a gelatin scaffold, a gelatin/galectin-3
scaffold (6.7 μg/mL), or left empty (control). Sections show the wound edge for each
condition and the epithelial tongue. (A) Images shown of the four treatment conditions
are from one mouse at day 5 and one mouse at day 7. (B) Images shown of the four
treatment conditions are from a different mouse at day 5 and a different mouse at day 7 to
show the variability between mice. S=scaffold, N=3, scale bar: 500μm.
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2.3.9 The Influence of Topical Galectin-3 and Gelatin/Galectin-3
Scaffolds on Macrophage Populations in WT and Diabetic Mice
During Healing
To determine the effect of gelatin/galectin-3 scaffolds on re-epithelialization at earlier
time points, full thickness excisional wounds were created in WT and db/db mice and
received one of 4 treatments: empty (control), topical galectin-3 (6.7 μg/mL), a gelatin
scaffold, or a gelatin scaffold containing 6.7 μg/mL galectin-3.
In the WT mice, there were no observable differences in the amount of arginase Ipositive macrophages across the four treatment groups at day 5 (Figure 2.21). At day 7
post-surgery, there qualitatively appeared to be more arginase I-positive macrophages in
the wounds treated with topical galectin-3 (Figure 2.21). Quantification revealed that the
mean density of arginase I-positive macrophages in the wounds was not statistically
significant between treatment conditions at day 7 (N=3, n=3, p>0.05) and is shown in
Figure 2.22. Differences in the number of iNOS-positive macrophages were not observed
across the four treatment groups at days 5 or 7 (Figure 2.21).
In the db/db mice, there were no observable differences in the amount of arginase Ipositive macrophages at days 5 and 7 following wounding (Figure 2.23). There were also
no discernable differences in the amount of iNOS-positive macrophages at day 5 and day
7 post-wounding (Figure 2.23).
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Figure 2.21 – Macrophage populations during in vivo full thickness wounding in WT
mice: Full thickness excisional wounds measuring 6 mm in diameter were treated with
topical galectin-3 (6.7 μg/mL), a gelatin scaffold, a gelatin/galectin-3 scaffold (6.7
μg/mL), or left empty (control). Sections show the relative amounts of arginase I-positive
macrophages (green) and iNOS-positive macrophages (red) in the wound bed for each
treatment condition. Cell nuclei are shown in blue. Images shown are representative of
sections collected from three separate mice (N=3). (A) At day 5, there are no qualitative
differences in the amount or localization of arginase I-positive macrophages and iNOSpositive macrophages. At day 7 there qualitatively appeared to be more arginase Ipositive macrophages in wounds treated with topical galectin-3. At day 7 there are no
discernable differences in the amount of iNOS-positive macrophages across the four
treatment conditions. Scale bar: 500μm. (B) Higher magnification images of the areas in
(A) indicated by grey boxes. Scale bar: 110μm.
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Figure 2.22 – Quantification of arginase I-positive macrophages within the wound
bed of WT mice at day 7: Full thickness excisional wounds measuring 6 mm in
diameter were treated with topical galectin-3 (6.7 μg/mL), a gelatin scaffold, a
gelatin/galectin-3 scaffold (6.7 μg/mL), or left empty (control). The density of arginase Ipositive macrophages within the wound was determined in WT mice at day 7 following
wounding using three sections from each of the three mice (N=3, n=3). Although the
overall density of arginase I-positive macrophages in the wounds was higher in wounds
treated with topical galectin-3, the differences were not statistically significant. N=3, n=3,
one-way ANOVA, Tukey post-test for multiple comparisons, p>0.05. All data is
represented as mean ± SD.
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Figure 2.23 – Macrophage populations during in vivo full thickness wounding in
db/db mice: Full thickness excisional wounds measuring 6 mm in diameter were treated
with topical galectin-3 (6.7 μg/mL), a gelatin scaffold, a gelatin/galectin-3 scaffold (6.7
μg/mL), or left empty (control). Sections show the relative amounts of arginase I-positive
macrophages (green) and iNOS-positive macrophages (red) in the wound bed for each
treatment condition. Cell nuclei are shown in blue. Images shown are representative of
sections collected from three separate mice (N=3). (A) At days 5 and 7, there are no
qualitative differences in the amount or localization of arginase I-positive macrophages
and iNOS-positive macrophages in the wound bed. Scale bar: 500μm. (B) Higher
magnification images of the areas in (A) indicated by grey boxes. Scale bar: 110μm
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2.4 Discussion
Chronic skin wounds are problematic as they persist in a pro- inflammatory state, unable
to progress to the proliferative phase and restore the barrier function of the epithelium
(13). Galectin-3 is a protein that has previously been implicated in monocyte migration
(22), alternative macrophage activation (24), and increased re-epithelialization in corneal
wounds (25, 40). The use of exogenous galectin-3 in treating full thickness skin wounds
has yet to be explored. We hypothesized that local delivery of galectin-3 could regulate
inflammation and increase re-epithelialization in skin healing, ultimately leading to
wound closure. An electrospun scaffold structure was used to deliver galectin-3 as it
provides a large surface area for distribution of the protein, for cell adhesion and
migration, and to protect it from biodegradation (28, 41). The aim of this study was to
assess the efficacy of an electrospun gelatin scaffold loaded with the matricellular protein
human galectin-3 for applications in skin healing.
Type B Bovine gelatin was used as the main structural component of the scaffold. We
selected gelatin as it is derived from collagen (42), which represents the primary
structural protein of the dermal extracellular matrix (43). Thus, gelatin provides some
chemical similarity to the extracellular matrix while reducing cost of scaffold fabrication
(44). In this thesis, electrospinning was used as the fiber fabrication method. While many
studies have used collagen as the structural unit in electrospinning, its use is controversial
as previous reports have demonstrated that collagen loses its tertiary structure following
electrospinning and fibers generated are typically similar to gelatin in structure (45).
Gelatin has previously been electrospun by several groups, with results showing good
biocompatibility of the generated scaffolds, including a study demonstrating increased
wound closure in a full thickness wound healing model in rats (34-37). Electrospun
gelatin scaffolds, both alone and in combination with other polymers, have also been
used with success for the delivery of growth factors and bioactive compounds (46-48).
Furthermore, the biodegradability of gelatin can be tuned to facilitate protein delivery
using glutaraldehyde crosslinking, in which aldehyde groups from glutaraldehyde react
with lysine or hydroxylysine residues to form aldimine linkages (-C=N-) (49, 50).
Subsequent quenching of the scaffolds in 0.1M glycine is used to block unreacted
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aldehyde groups (51). Electrospinning of Type B Bovine gelatin was performed using
40% v/v acetic acid as a solvent. Use of 40% v/v acetic acid has previously been used for
the electrospinning of collagen, demonstrating bead free fibers in the 100-200 nm range
along with several other concentrations of this solvent (52, 53). Electrospinning with
acetic acid is advantageous as it avoids the use of fluoroalcohols, which are highly
cytotoxic and can cause the loss of tertiary structure and changes in the secondary
structure of proteins (54).
The first objective of the thesis was to refine scaffold manufacturing protocols,
specifically to determine electrospinning parameters that would provide bead-free and
ribbon-free fibers with diameters measuring within the range of the native extracellular
matrix (ECM). The polymer solution flowrate, distance between the needle tip and
collector (collector distance), and the concentration of the polymer have all previously
been reported to influence the resulting electrospun fiber diameter and morphology (43,
55, 56). Therefore, to identify an appropriate combination of these parameters, three
concentrations of gelatin, three flowrates, and three collector distances were tested by
electrospinning at each set of parameters listed in Table 1.
Changing the flowrate was not found to significantly influence the resulting mean fiber
diameter. As a result, a flowrate of 0.5 mL/h was selected for subsequent electrospinning
as using a higher flowrate decreases the amount of time required for electrospinning and
decreasing time over which the protein is exposed to the solvent. Similarly, changing the
collector distance did not influence the resulting mean fiber diameter. A collector
distance of 10 cm was selected for subsequent electrospinning as this resulted in a wider
distribution of fibers on the rotating mandrel, creating a larger scaffold surface area,
without depositing fibers outside of the mandrel.
Consistent with other studies, increasing the concentration of gelatin resulted in an
increase in the fiber diameter (37, 51, 57). Although differences in fiber diameter
resulting from 20% weight and 25% weight gelatin were not considered significant, the
frequency distribution plot highlighted that when 20% weight gelatin is used, more fibers
fall within the 100-200 nm range, and there is a narrower distribution of fiber diameters

116

at this concentration, making it more reflective of the native tissue ECM which has fiber
diameters within the range of 30-130 nm (44). However, use of 20% weight gelatin
produced detectable amounts of beaded fibers, which are thought to negatively impact
cellular interactions with scaffolds (58). Additionally, ribbon-like fibers, which do not
reflect the morphology of collagen fibrils in the native tissue, were detected at both 25%
weight and 30% weight gelatin. Therefore, additional experiments were conducted to
determine whether increasing the gelatin concentration to 21% weight would eliminate
the fibrous beads, while retaining a small fiber diameter. As expected, the resulting
scaffolds were free of beaded fibers and did not exhibit ribbon-like fibers. Although the
fiber diameter was increased, the frequency distribution of the fibers showed that the
fiber sizes remained within range of collagen fibril sizes found in human tissues (33).
In the fabrication of electrospun scaffolds, a high porosity is preferable to support cell
ingrowth and to facilitate the diffusion of waste and nutrients (59). The porosity obtained
in the refined scaffolds fell within the range of porosities shown in scaffolds electrospun
using a variety of polymers and electrospinning parameters, ranging from approximately
60-90% (34, 60, 61). The pore size distribution was also comparable to those seen for
electrospun gelatin (34, 60). Although the obtained porosity is reasonable, obtaining a
porosity of 90% has been suggested to be ideal (59). The electrospun scaffolds in this
study had a low average pore diameter (pore size) of 1.15 μm. Having more pores in the
50-100 μm range would have also been preferable to coincide with the size of the cells on
the scaffold and support their infiltration. In fact, scaffolds having pore sizes of
approximately 100 μm and porosity in the 90% range have been shown to support the
infiltration of cells from the surface of the scaffold (62). However, it is difficult to obtain
scaffolds having both pore sizes in this range and fiber sizes in the 100 nm range as
decreasing fiber size is associated with decreasing pore sizes (63). To overcome this
problem, several groups have employed strategies whereby substances including salt, or
simultaneously-electrospun secondary polymers (sacrificial fibers) are deposited within
the mat during the electrospinning process and are later removed. This process has
resulted in increased scaffold infiltration by cells (64, 65).
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Recombinant human galectin-3 was added to the electrospinning solution during scaffold
fabrication to achieve a final concentration of 6.7 μg/mL. This concentration was chosen
as it fell within the range used by other groups to achieve effects in vitro. For example, in
studies in skin, concentrations as low as 1μg/mL have been used to increase keratinocyte
migration speed (27) and galectin-3 has previously been shown to have a concentration
dependent effect on monocyte recruitment from 0.001-0.01 μM (66). Additionally, the
use of 6.3 μg/mL promotes human keratinocyte migration, while use of higher
concentrations (50 μg/mL) can inhibit migration in vitro (67). Detection of galectin-3
protein sequences from scaffold samples confirmed that the blend electrospinning method
could generate scaffolds with galectin-3 dispersed throughout the fibers. The sequences
identified are located within the protein’s CRD, which is important as this domain is
required for many of the proteins functions (23-25, 68). Identification of galectin-3 was
expected, as several groups have previously used the blend electrospinning method for
the delivery of matricellular proteins and growth factors (31, 46-48).
During healing, the granulation tissue is essential in guiding cells into the wound by
supporting their adhesion and migration (1). Therefore, in order to appropriately mimic
the extracellular matrix, it is imperative that the scaffolds support the adhesion and
proliferation of cells (43). The ability of cells to adhere and proliferate on the scaffolds
was therefore used as a measure of biocompatibility. Dermal fibroblasts were used for the
study as they interact with and remodel the granulation tissue during healing (1, 14). The
initial adhesion of human dermal fibroblasts was improved relative to the tissue culture
plastic in both gelatin and gelatin/galectin-3 scaffolds. This improved adhesion in both
the gelatin and gelatin/galectin-3 scaffolds likely results from the arginine-glycineaspartate (RGD) sequences contained within gelatin, which promote cell adhesion
through integrin binding (69, 70). The improved adhesion in both scaffolds can also be
attributed in part to the increased surface area that the scaffolds offer for attachment,
further promoting cell matrix interactions (32). Over a two-week period, the proliferation
profile of human dermal fibroblasts on the gelatin and gelatin/galectin-3 scaffolds was
consistent with that of the tissue culture plastic controls. This finding confirms that both
the gelatin and gelatin/galectin-3 scaffolds are non-toxic and can support cell growth,
eliminating concern regarding the use of glutaraldehyde as a crosslinking agent. Our
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findings are consistent with other groups who have shown consistent proliferation of
human dermal fibroblasts between gelatin scaffolds and tissue culture plastic controls
(35, 37). Proliferation on scaffolds that is consistent with culture on tissue culture plastic
is an important finding, as scaffolds made from other materials, including chitosan and
polycaprolactone, have demonstrated reduced rates of proliferation (35, 71).
Surface topography can influence cell responses including adhesion, migration and
differentiation (72). When cultured on gelatin and gelatin/galectin-3 scaffolds, human
dermal fibroblasts exhibited a spindle-like morphology and showed alignment of their
actin filaments. This positive interaction between dermal fibroblasts and gelatin scaffolds
has also been noted by other groups, who have shown cell spreading and alignment on
gelatin scaffolds (34, 35, 37). Ensuring that fibroblasts portray a spindle-like morphology
is significant, as cell spreading is important for cell viability in adherent cell types (73). A
rounded morphology in fibroblasts is associated with cell detachment (74), which would
have implied cytotoxicity of the scaffolds (75). Both gelatin and gelatin/galectin-3
scaffolds also supported the deposition of fibronectin by fibroblasts, indicating dermal
fibroblasts are able to synthesize extracellular matrix while cultured on the scaffolds.
Fibronectin deposition by fibroblasts is important during wound healing, as it mediates
cell adhesion and migration, stimulates collagen deposition, and contributes to wound
contraction (76).
Based on the evidence suggesting that the scaffolds were biocompatible in vitro, the
influence of the scaffolds on wound closure kinetics in mouse models of normal and
impaired wound healing were investigated. The use of gelatin scaffolds with and without
the addition of a low and high concentration of galectin-3 did not significantly alter the
wound closure kinetics in both WT and db/db mice over the 17-day period. At day 17 the
appearance of cells were consistent with fibroblasts and collagen production in the
wounds suggest that use of scaffolds did not result in a foreign body response (77). The
addition of topical galectin-3 also did not increase closure at day 5 or 7, but this does not
eliminate the possibility of changes early in the inflammatory phase which do not
manifest in measurable closure changes. Although treating wounds with topical galectin3 and scaffolds containing galectin-3 did not significantly increase wound closure

119

kinetics, this is supported by the finding that wound closure kinetics are not impaired in
galectin-3 knockout mice, which also show no differences in immune cell infiltration,
angiogenesis, or fibrotic response (26). Interestingly, use of gelatin scaffolds alone has
previously been reported to increase wound closure in a full thickness skin model in rats,
which is in contrast to our findings (34). However, several factors could have contributed
to the differences in the results obtained by Dubsky et al., including their use of rats as an
animal model rather than mice, the difference in size of the initial wounds, and their use
of TegadermTM to cover the wounds throughout the study. Dubsky et al. also covered
control wounds with wetted gauze and the scaffolds were placed over the wound rather
than being tucked under the surrounding tissue (34).
During wound healing, keratinocyte proliferation and migration is stimulated by growth
factors including epidermal growth factor (EGF) (14), resulting in their migration over
the dermis to restore the epithelial barrier (1). Studies of dermal healing have
demonstrated that galectin-3 knockout mice exhibit impaired re-epithelialization, which
manifests in decreased length of the epithelial tongue, and therefore decreased reepithelialization at days 2 (27) and 7 (26) post-wounding. This deficient reepithelialization was attributed to a migratory defect in keratinocytes caused by aberrant
EGFR endocytosis and recycling, which cytosolic galectin-3 was shown to mediate
through binding to ALIX (27). When recombinant human galectin-3 was added to
wounds of WT mice topically or using a gelatin scaffold, differences in epithelial
thickness were not quantified at days 5 or 7 post wounding. Similarly, differences were
not observed in db/db mice at these time points. This result was consistent with previous
reports showing no defect in epithelial thickness in galectin-3 knockout mice (26, 27).
Differences in re-epithelialization were also not observed in both WT and db/db mice at
day 5 and 7 following wounding which was consistent with the finding that exogenous
galectin-3 was not effective in correcting the defective EGFR endocytosis and recycling
in galectin-3 knockout mice (27, 50). In contrast, studies of corneal healing have shown
that exogenous human recombinant galectin-3 can increase re-epithelialization in WT
mice (25) and in monkey corneal explants (40). However, this increase was suggested to
be attributed to the modulation of galectin-7 by exogenous galectin-3, as galectin-7 was
found to accelerate re-epithelialization in galectin-3 knockout mice and mouse embryonic
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fibroblasts from galectin-3 knockout mice showed reduced levels of galectin-7 (25).
Studies in skin, which show that gene expression of galectin-7 is not altered at day 7
following wounding in WT mice, imply that the mechanism suggested to account for
increased re-epithelialization in the cornea might not apply to the skin (26). This
discrepancy highlights the issue of the context-specific roles of matricellular proteins
(78).
In wound healing, inflammation follows hemostasis, a process during which monocytes
are recruited to the wound by chemoattractants and differentiate into macrophages (2).
Macrophages are vital constituents of the wound healing process, mediating wound
healing through the release of regulatory molecules which is based on their phenotype
(79). Classically activated (M1) macrophages produce nitric oxide and secrete proinflammatory cytokines including TNF-α, IL-1, IL-6, and IL-12, while alternatively
activated macrophages (M2) are implicated in tissue remodeling and secrete TGF-β (80).
Galectin-3 has previously been implicated in macrophage function (23, 24, 66); therefore
macrophage populations in WT and db/db mice were investigated after treatment with
topical galectin-3 and gelatin/galectin-3 scaffolds in order to discern whether exogenous
human recombinant galectin-3 could increase the number of M2 polarized macrophages.
Macrophage populations appeared unchanged following treatments in db/db mice at both
time points. In WT mice, differences were not observed at day 5. At day 7, there
qualitatively appeared to be more M2 macrophages in wounds treated with topical
galectin-3, although quantification showed no significant differences in M2 macrophage
density across the four treatment groups. This result was unexpected as Mackinnon et al.
reported that bone marrow derived macrophages (BMDMs) from galectin-3 knockout
mice show a defect in IL-4 and IL-13 M2 macrophage polarization in vivo and in vitro
(24). In addition they showed that IL-4 and IL-13 can stimulate galectin-3 upregulation
and release in BMDMs (24). Of note, this study did not test the addition of exogenous
galectin-3, therefore there is currently no indication as to whether it’s use would be
sufficient in rescuing the deficient M2 polarization of BMDMs in galectin-3 knockout
mice. It is also possible that the effect of exogenously added human recombinant
galectin-3 occurs at earlier time points as the number of galectin-3-positive cells peak at
one day following wounding in WT mice (78). Or perhaps, exogenous galectin-3 alone is
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not sufficient in upregulating the expression of surface bound galectin-3, the secretion of
galectin-3 or upregulating CD98 which are each implicated in the suggested autocrine
loop that controls M2 activation (24). As human and murine galectin-3 share only 80%
homology (81), another possibility is that the differences in homology of these species
contribute to the lack of functionality of exogenous galectin-3 in this feedback loop.

2.5 Conclusion
In summary, blend electrospun gelatin/galectin-3 scaffolds have been developed which
show biocompatibility when tested both in vitro and in vivo. Using human dermal
fibroblasts, scaffolds increased initial cell adhesion, supported their proliferation over a
14 day period and supported their production of the extracellular matrix protein
fibronectin. In vivo, use of the scaffolds in excisional wounds in WT and db/db mice did
not delay healing or result in a foreign body response at day 17. Use of topical galectin-3
and gelatin/galectin-3 scaffolds did not affect wound closure, epithelial thickness, or reepithelialization in WT and db/db mice, or influence the amount of M1 or M2
macrophages in WT and db/db mice. Future work should explore the exact pathological
contexts in which galectin-3 can modulate inflammation.
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Chapter 3

3

General Discussion

3.1 Summary and Final Conclusions
Objective 1: To develop a scaffold for the delivery of exogenous galectin-3
Electrospinning

parameters

that

influence

fiber

formation

were

investigated,

demonstrating that altering the flowrate and collector distance did not significantly
change the resulting electrospun fiber diameters. The largest variable identified was the
concentration of gelatin in the polymer solution used for electrospinning: at 20% weight
gelatin, the fiber diameters were smaller, with some fibers showing beads; while at higher
concentrations, fiber diameters increased significantly and displayed a ribbon-like
structure. By electrospinning using a polymer solution with 21% weight gelatin, a
flowrate of 0.5 ml/h and a collector distance of 10 cm, the resulting fibers had diameters
within the range of extracellular matrix fibers found in dermis. Scaffolds exhibited a high
porosity, but the average pore diameter was approximately 1μm, which is not conducive
to cell infiltration. Detection of four sequences from the human galectin-3 carbohydrate
recognition domain were identified using mass spectroscopy from within a crosslinked
gelatin/galectin-3 scaffold validating that galectin-3 was incorporated into the gelatin
scaffolds using the blend electrospinning method.
Objective 2: To evaluate the biocompatibility of the gelatin/galectin-3 scaffolds in vitro
using human dermal fibroblasts
Gelatin and gelatin/galectin-3 scaffolds were shown to increase the adhesion of human
dermal fibroblasts 1 hour after seeding compared to tissue culture plastic, as well as
supporting their proliferation over a two-week period. Human dermal fibroblasts also
spread and elongated on the scaffold fibers, and secreted fibronectin while cultured on
both the gelatin and gelatin/galectin-3 scaffolds. These findings demonstrated that the
scaffolds were biocompatible in vitro, with no cytotoxic response evident in the cells.
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Objective 3: To evaluate the effect of the gelatin/galectin-3 scaffold on wound healing in
murine models
a. Assess the influence of the scaffold on wound closure kinetics
Treatment of wounds with gelatin and gelatin/galectin-3 scaffolds did not alter wound
closure kinetics in either wild type (WT) or diabetic (db/db) mice. Collagen production
and the appearance of cells consistent with fibroblasts in the tissue of db/db mice showed
that use of the scaffolds did not result in a foreign body response at 17 days.
b. Compare and contrast the efficacy of local delivery of topical galectin-3 versus
gelatin/galectin-3 electrospun scaffolds on re-epithelialization and macrophage
polarization during skin healing.
Treatment of wounds with either topical galectin-3 or gelatin/galectin-3 scaffolds caused
no measureable effect on processes associated with re-epithelialization in WT and db/db
mice at the time points assessed. No significant differences were observed qualitatively in
the numbers of M1 or M2 macrophages in db/db mice at either time point, or in WT mice
at day 5 following wounding. At day 7, qualitative assessment suggested that more
arginase I-positive macrophages were present in wounds treated with topical galectin-3.
Although quantification revealed that the density of arginase I-positive macrophages was
higher in these wounds, the results were not significant. Taken together, these findings
suggest that exogenous galectin-3 is not sufficient for stimulating re-epithelialization in
skin. However, the role of topical galectin-3 as a therapeutic for M2 macrophage
polarization requires future investigation.

3.2 Contributions to the Current State of Knowledge
3.2.1 Galectin-3 as a Modulator of Re-epithelialization
Galectin-3 is a matricellular protein that has been implicated in processes associated with
both the inflammatory and proliferative phases of healing. Studies using experimentallycreated defects in the cornea and skin of knockout mice have identified defects in reepithelialization in the absence of galectin-3, in comparison with the same process in WT
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mice (1-3). Re-epithelialization is an essential process during skin healing, restoring
barrier function (4). Cao et al. have shown that when applied to knockout mice, human
recombinant galectin-3 was able to increase re-epithelialization in WT but not knockout
mice, which was attributed to its effect on the upregulation of galectin-7, a protein shown
to increase re-epithelialization in both phenotypes (1). In contrast to this research, we
report here that local delivery of galectin-3 to both WT and db/db mice, does not increase
re-epithelialization. Although the concentration used in our study (6.7μg/mL) was lower
than the concentration used in the cornea (10 and 20μg/mL), it was consistent with the
concentration of 6.3 μg/mL previously used to stimulate keratinocyte migration in vitro
through laminin 322 binding (5) and with Liu et al., who also showed a pro-migratory
effect when human recombinant galectin-3 was added at 1μg/mL to keratinocytes from
WT mice in vitro (2). Our findings, together with the finding that defective epidermal
growth factor receptor endocytosis (which is controlled via cytosolic galectin-3 rather
than secreted galectin-3) is the mechanism responsible for impaired re-epithelialization in
galectin-3 knockout mice in skin (2), suggest that galectin-3 may not be effective in
promoting re-epithelialization in a recombinant form or when delivered into the
extracellular microenvironment.

3.2.2 Galectin-3 as a Modulator of Inflammatory Processes
With respect to inflammation, galectin-3 typically shows a higher gene and protein
expression in M2 polarized macrophages (6). It has also been shown to be a
chemoattractant for monocytes and macrophages (7), and increases the infiltration of
tumors by M2 macrophages in mice (8). These findings, together with its reported role in
regulating M2 macrophage polarization (9), suggested that it could represent a legitimate
therapeutic for mediating inflammation during skin healing in vivo. The findings of this
thesis do not support a definite connection between the use of exogenous recombinant
human galectin-3 in dermal wounds in vivo with an associated change in the amount of
M2 macrophages at days 5 and 7 following wounding. Similar infiltration of M2
macrophages in the dermal wounds left empty, treated with topical galectin-3, or treated
with gelatin/galectin-3 scaffolds during healing is consistent with previous studies from
our laboratory showing that compared to WT mice, galectin-3 knockout mice do not
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exhibit differences in the abundance of M1 or M2 macrophages during the inflammatory
phase of healing (3). This is not the first discrepancy in the literature pertaining to the
role of galectin-3 during inflammation as the finding by Mackinnon et.al that exposure of
bone marrow derived macrophages to 100 ng/mL lipopolysaccharides (LPS) suppressed
the expression and secretion of galectin-3 (9) was in contrast to the finding by Novak et
al. who reported that treatment of human blood-monocyte derived macrophages exposed
to 100 ng/mL LPS and 20 ng/mL interferon gamma showed a significant increase in
galectin-3 expression (6). This discrepancy demonstrates the issue of the context-specific
roles of the protein (10). Another key issue, in elucidating the role of galectin-3 on
macrophage polarization, is that its characterization in vitro may not necessarily translate
in vivo as factors contributing to polarization in vivo, including cell maturation, matrix
composition and chemoattractants, are often overlooked (11).
The results of this thesis suggest that in a recombinant form delivered extracellularly,
there is a lack of evidence to support galectin-3 in increasing re-epithelialization or
modulating inflammation and that galectin-3 in a recombinant form may not be an
effective therapeutic for treating chronic skin wounds. However, in order to completely
dismiss the protein as a therapeutic for this application, further work needs to be
performed to elucidate the exact pathological contexts in which galectin-3 can modulate
inflammation.

3.2.3 Models of Impaired Healing and Galectin-3
Some groups have suggested that galectin-3 signaling can be either pro-inflammatory or
anti-inflammatory and depends on the pathophysiological state of the microenvironment
(12). Considering this hypothesis, it is conceivable that in a chronic wound environment
in humans, where bacterial colonization can easily occur (13) and where levels of proinflammatory cytokines and reactive oxygen species are exacerbated (14), that the
delivery of the exogenous galectin-3 would exhibit a modulatory effect on the state of
inflammation. However, no animal model can accurately mimic the microenvironment
within a human chronic skin wound, such that the complexity and heterogeneity of these
wounds can be fully recapitulated (15). This issue is due in part to the multiple factors
that can contribute to the development of a chronic wound, including infection,
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malnutrition, hyperglycemia, and vascular insufficiencies, which are not reflected
together in animal models (13). Rather, most animal models in mice are monogenic
models of obesity and diabetes, limiting their clinical translation to humans (16). The
variability between patients in the cell populations and proteins that are present in the
wound bed also make translation from animal models difficult (17). As a result, many
therapeutic targets, including several growth factors, have shown promise for improving
healing in animal models, but lack efficacy or fail completely in clinical trials (18, 19).
One such growth factor is vascular endothelial growth factor (VEGF). Pre-clinical studies
showed that when applied topically, VEGF can accelerate healing in db/db mice (20), yet
a phase I trial in chronic neuropathic diabetic foot ulcers found no significant differences
between the reduction in total ulcer surface area in wounds treated with topical VEGF
relative to placebo-treated wounds after 29, 43, and 84 days (21). The study also failed to
meet its primary exploratory endpoint of reduced total ulcer surface area at 43 days (21).
Furthermore, recent clinical studies on platelet derived growth factor, which is the only
growth factor currently approved by the Food and Drug Administration (22), show that it
does not significantly improve healing in diabetic foot ulcers relative to those treated with
an offloading cast, casting doubt on its efficacy (23).

3.2.4 The Efficacy of Matricellular Proteins as Therapeutics
Matricellular proteins are non-structural components of the extracellular matrix that are
normally not expressed in adult tissue, but become upregulated during wound healing and
pathological processes. Matricellular proteins exhibit tightly regulated expression
patterns, acting spatially and temporally to control specific cell behaviours, making them
ideal candidates as therapeutics in wound healing (24). The topical application of
matricellular proteins has been previously investigated in wound healing in mice in vivo.
The topical application of exogenous cysteine-rich angiogenic inducer 61 (CCN1) was
able to reverse the profibrotic phenotype of CCN1 knockin mice that expressed a
senescence-defective CCN1 mutant, increasing expression of matrix metalloproteinases
(MMPs) and decreasing expression of transforming growth factor beta (TGF-β) (25).
Another matricellular protein, angiopoietin-like 4, significantly accelerated wound
closure relative to saline when applied topically to full thickness excisional splint wounds
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in ob/ob mice (26). Similarly, the subcutaneous injection of recombinant human galectin1 in wounds of WT and streptozotocin-induced diabetic mice also led to accelerated
closure (27). Our laboratory has shown that scaffolds can also be used to deliver
matricellular proteins, resulting in effects beneficial to the wound healing process.
Delivery of persiostin via an electropsun collagen scaffold was able to recover alpha
smooth muscle actin expression in periostin knockout mice (28). Additionally, the
delivery of periostin and connective tissue growth factor (CCN2), alone or in
combination, using an electrospun collagen scaffold significantly accelerated closure in
full thickness excisional wounds in db/db mice relative to empty controls (Hamilton
Laboratory, unpublished data). In our study, we show that delivery of exogenous
galectin-3 either topically, or using an electrospun gelatin scaffold, has shown the lowest
efficacy in vivo for improving and accelerating the repair of full thickness excisional skin
wounds.

3.2.5 Galectin-3 Bioactivity
An important consideration in assessing the lack of efficacy of both topical and scaffold
delivery of galectin-3 is the bioactivity of the protein. Post-translational modifications
can have significant impacts on the biological function of a protein (29). Galectin-3 is
known to undergo several types of post-translational modifications including cleavage,
phosphorylation, and acetylation, each having implications on the protein’s function (30).
For example, galectin-3 can undergo cleavage at multiple sites, including at alanine62tyrosine63 by MMPs 2, 7, 9, and, 13, that results in two distinct peptides and inhibits
processes requiring N-terminal self-association of the protein (30). The protein can also
be phosphorylated at tyrosine79, tyrosine107, and tyrosine118 by c-Abl (31), and by casein
kinase I at serine6 (32). Phosphorylation can regulate its binding to ligands, its cellular
distribution, and its apoptotic activity (30). Additionally, in galectin-3 isolated from rat
lung, alanine2 can be acetylated (33). Therefore, the activity of galectin-3 is dependent on
many extrinsic microenvironmental factors and it is conceivable that although the protein
in its recombinant form is able to agglutinate red blood cells (as provided by the
manufacturer) (34), it may not contain the post translational modifications required for its
function in triggering M2 macrophage polarization. Other matricellular proteins also
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exhibit post-translational modification-dependent effects. For example, osteopontin has
multiple isoforms with differing degrees of phosphorylation that depend on the cell type
from which it is produced. As a result, the effects of the interaction of this protein with
cell receptors change depending on its phosphorylation state (35). Therefore, future work
should focus on determining the exact contexts in which recombinant human galectin-3
can influence macrophage function.

3.3 Future Directions
3.3.1 Improving Scaffold Pore Size
In addition to a high porosity, large pore sizes are important to ensure the infiltration of
the scaffolds by cells (36, 37). Co-electrospinning with sacrificial fibers that can be later
removed in solution is one way to increase the pore area within electrospun scaffolds
(38). Co-electrospinning of gelatin scaffolds with micrometer sized polyethylene glycol
fibers has previously been conducted to increase the pore size of scaffolds from 1 μm to
10-100 μm whereby polyethylene is removed using tert-butanol following crosslinking
(39). For our purposes, poly ethylene oxide (PEO) would be a good candidate as it is
highly soluble in water, which would allow removal following gelatin crosslinking (38).
Klumpp et al. used this method for the electrospinning of a polycaprolactone/collagen
blended scaffold with PEO as their sacrificial fiber. Following soaking in water, they
were able to create a scaffold with dense pockets and open sites for cell infiltration (40).
In vivo they were able to show complete infiltration of their scaffolds after 4 weeks in a
model of vascularization in rats (40). Using this method to improve porosity in the
electrospun scaffolds could promote cell infiltration of our scaffolds in vivo during
excisional healing.

3.3.2 Establishing Galectin-3 Bioactivity In Vitro and In Vivo
One of the findings from this thesis relates to the bioactivity of the recombinant human
galectin-3 protein used in this study. The bioactivity of the protein was quantified by
R&D systems based on its ability to agglutinate red blood cells. A paper by Hadari et al.
is referenced, which stated that galectin-3 bioactivity was measured in this manner using
rabbit erythrocytes (34). Other groups have reported testing galectin-3 bioactivity by
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treating a Jurkat acute T-cell leukemia cell line with 15 μM of the protein for 6 hours and
measuring cell viability (6), as the protein has previously been shown to induce apoptosis
in these cells (41). Our study showed a lack of efficacy of recombinant human galectin-3
when added to wounds either topically or in combination with a gelatin scaffold.
Assessing whether the protein had low bioactivity is further compounded by the findings
from our laboratory that show galectin-3 knockout mice do not display an impairment in
closure of full thickness excisional wounds (3). Moreover, it is now known that galectin3 contains several sites through which activity can be modified by post translational
modifications, which may be required in order to generate the desired activities
associated with the protein (30). Therefore, it appears that a well-developed assay for
detection of recombinant human galectin-3 bioactivity is lacking. As a result, future work
should be conducted to quantify whether the protein used in the study has bioactivity
pertaining to macrophage function. As Mackinnon et al. have shown that bone marrow
derived macrophages from galectin-3 knockout mice exhibit reduced arginase I activity
from interleukin 4 (IL-4) and IL-13 activation, evaluating the influence of the protein on
macrophage polarization in vitro using the human monocytic cell line THP-1 might be an
appropriate area of investigation (9). It would be valuable to identify whether treatment
with exogenous recombinant human galectin-3 can upregulate M2 macrophage markers,
including TGF-β and the mannose receptor (MR) (42) in monocytes as well as M1 and
M2 macrophages. This study would elucidate whether the protein can induce a switch in
phenotype from M1 to M2 macrophages and if the protein can guide monocytic
differentiation towards an M2 phenotype. Testing of various concentrations would also
be appropriate as galectin-3 exhibits concentration dependent effects in vitro and would
provide a better measure for translation to in vivo studies (7, 43). Once the bioactivity can
be reproducibly established in vitro, investigation of its role in vivo via topical delivery in
comparison to untreated wounds could again be explored using a larger number of
animals to increase the power of the study. Furthermore, elucidating the role of galectin-3
at earlier time points during healing would be interesting, as the number of galectin-3positive cells peak at one day following wounding in WT mice (10).
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3.4 Limitations
3.4.1 Animal Model
Chronic skin wound development is extremely complex and multifactorial, with
infection, aging, malnutrition and systemic conditions including hyperglycemia and
vascular insufficiency each contributing to the exacerbation of inflammation (13). In
addition, these wounds exhibit heterogeneity across patients (13). As a result, no animal
model exists that can fully recapitulate the multifactorial nature and complexity of
human chronic wounds (15). The animal model selected in this study was the db/db
monogenic mouse model of type 2 diabetes. While this model does show prolonged
inflammation during healing (44), bacterial infection was not considered in the study
despite playing a contributing role in the delayed healing of human chronic wounds (45).
Furthermore, although this model has shown impaired wound contraction, it has been
suggested that this is attributed to the stretching of skin in these mice due to their obesity
rather than to the disease itself, limiting its translation to chronic wounds in diabetic
patients (16).

3.4.2 Calculation of Wound Size and Number of Animals Used in
Mouse Studies
In calculating wound closure kinetics, one limitation is the formation of the eschar which
covers the underlying healing tissue. Calculations of the wound area included the eschar
present on the surface of the skin. The eschars were not manipulated or removed in any
of the animals throughout the study and left to fall off naturally as manipulation could
have disrupted the underlying tissue. As a result, calculated wound areas could have
appeared larger due to the presence of the eschar, despite the underlying tissue being
healed. The validity of the mouse studies conducted at earlier time points are also limited
by the low number of mice used for each condition and at each time point. Including
more mice in the study would have improved the power of the study, providing stronger
evidence of the findings.
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3.5 Final Summary
This thesis demonstrated that both gelatin and gelatin/galectin-3 scaffolds can be
electrospun, creating a scaffold with an overall porosity of approximately 83% and
average pore diameter of approximately 1.15μm. Both gelatin and gelatin/galectin-3
scaffolds can support the adhesion, deposition of matrix and proliferation of human
dermal fibroblasts in vitro providing evidence that they are biocompatible. In vivo, both
gelatin and gelatin/galectin-3 scaffolds did not increase wound closure kinetics, yet did
not induce a foreign body response in db/db mice at day 17. Treatment of wounds with
topical galectin-3, gelatin and gelatin/galectin-3 scaffolds did not enhance reepithelialization or influence macrophage phenotypes in the wound, demonstrating a lack
of efficacy for use of galectin-3 in modulating these processes in mice. Future work
should elucidate the exact pathological instances in which galectin-3 might modulate
inflammation.
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Appendices
Appendix A: Standard curves for the quantification of cell numbers using the
CyQUANT® Cell Proliferation Assay Kit.
The fluorescence values were converted into cell numbers using a standard curve
generated using human dermal fibroblasts. A) Sample standard curve used for cell
number quantification in adhesion assay. B) Sample standard curve used for cell number
quantification in proliferation assay.
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Appendix B: No primary antibody negative control for fibronectin
immunofluorescence.
The deposition of the extracellular matrix protein fibronectin was visualized using
immunocytochemistry. Fibronectin is shown in green and cell nuclei are shown in blue.
Negative control images were taken of sections that were stained without the use of the
primary antibody. Negative control images were used to set the threshold values for
fibronectin fluorescence. Scale bar = 50μm.
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Appendix C: No primary antibody negative control for arginase I /iNOS
immunofluorescence.
The presence of M1 (iNOS+) and M2 (arginase I+) macrophages was visualized using
immunocytochemistry. M1 macrophages (iNOS+ cells) are shown in red and M2
macrophages (arginase I+ cells) are shown in green. Negative control images were taken
of sections that were stained without the use of the primary antibodies. Negative control
images were used to set the threshold values for fibronectin fluorescence. Scale bar =
500μm.
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